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The vaccinia virus I5L open reading frame encodes a 79-amino-acid protein, 
with two predicted transmembrane domains, conserved among all sequenced 
members of the chordopoxvirus subfamily. No nonpoxvirus homologs or functional 
motifs have been recognized, and the role of the I5 protein remains unknown. I5 
synthesis was dependent on viral DNA replication and occurred exclusively at late
times, consistent with a consensus late promoter motif adjacent to the start ofthe 
open reading frame. I5 was present in preparations of purified virions and could be 
extracted with nonionic detergent, suggesting membrane insertion. Transmission 
electron microscopy of immunogold-labeled thawed cryosections of infected cells 
revealed the association of an epitope-tagged I5 with the membranes of immature and 
mature virions. Viable I5L deletion and frameshift mutants were constructed and 
found to replicate like wild-type virus in a variety of cell lines, indicating hat the 
  
protein was dispensable for in vitro cultivation. However, mouse intranasal challenge 
experiments indicated that a mutant virus with a frameshift resulting in a stop codon 
near the N terminus of I5 was attenuated compared to control virus. The attenuation 
correlated with clearance of mutant viruses from the respiratory tract and with less 
progression and earlier resolution of pathological changes. We suggest that I5 is 
involved in an aspect of host defense that is evolutionarily conserved although a role 
in cell tropism should also be considered. 
The vaccinia virus A43R open reading frame encodes a 168-amino cid 
protein with a predicted N-terminal signal sequence and a C-terminal trasmembrane 
domain. Although A43R is conserved in all sequenced members of the orthopoxvirus 
genus, no non-orthopoxvirus homolog or functional motif was recognized. 
Biochemical and confocal microscopic studies indicated that A43 is expressed at late 
times following viral DNA synthesis and is a type-1 membrane protein with two N-
linked oligosaccharide chains. Neither mature nor enveloped virions contained 
appreciable amounts of A43, which was detected in Golgi and plasma membranes. 
Loss of A43R expression had no discernible effect on plaque size or virus replication 
in cell culture and little effect on virulence in a mouse intranasal infection model. 
Although the A43 mutant produced significantly smaller lesions in the skin of mice 
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Chapter 1: Literature Review 
1.1 Poxviridae 
1.1.1 Classification 
The Poxviridae encompass a group of large and complex DNA viruses. They 
have a single linear double stranded DNA genome with covalently closed hairpin 
termini, enzymes to synthesize mRNA, and unique to most DNA viruses, they 
replicate in the cytoplasm of their host cell [1].  There are two subfamilies belonging 
to the Poxviridae family, the Chordopoxviruses which infect vertebrates and the 
Entomopoxviruses which infect insects.  There are eight genera that belong to the 
Chordopoxvirus subfamily:  Avipoxvirus, Capripoxvirus, Leporipoxvirus, 
Molluscipoxvirus, Orthopoxvirus, Parapoxvirus, and Yatapoxvirus.  The 
Entomopoxviruses have three subfamilies recently renamed as the 
Alphaentomopoxviruses, Betaentomopoxviruses, and Gammaentomopoxviruses.  
Members within each genus are genetically and antigenically related, 
morphologically alike, and have a similar host range [1].   
1.2 The Orthopoxviruses 
The orthopoxviruses are the most studied of the poxviruses and infect a wide 
variety of hosts including humans, primates, cows, and rodents.  The most well 
known virus in this subfamily is variola virus (VARV), the etiological agent of 
smallpox, which was successfully eradicated from nature by vaccination with another 




1.2.1 Variola Virus 
1.2.1.1 A Historical Perspective 
VARV is the causative agent of smallpox, a major scourge in mankind’s 
history.  The name of the virus is derived from one of two Latin words, either “varus” 
meaning pimple or “varius” meaning spotted, for the pustules that form on an infected 
individual.   
Recent findings suggest that VARV likely diverged from an ancestral virus 
that was endemic in African rodents 16,000-68,000 years ago [2].  It seems 
reasonable to think that it most likely came into contact with early human hunters.  It 
was probably difficult for the virus to permanently establish itself in those small 
isolated hunting communities as an infection with the virus would lead to life-long 
immunity or death.  This limited the virus, allowing only for flare ups to occur once 
enough people in the community were susceptible.  The virus had to mutate, slowly, 
over a very long period of time to successfully integrate itself into the human 
population.  During this long period, while populations were increasing and cities 
were being established, genetic variants arose and new strains that could spread well 
predominated and eventually gave rise to the obligate human pathogen known today 
as VARV. 
The earliest known writings to describe smallpox first appeared in the 4th 
century A.D. in China, the 7th century A.D. in India and the Mediterranean, and the 
10th century A.D. in southwestern Asia [3]. In the early 1900s, paleopathologists 
examined the well kept tissues from mummies dating as far back as the Eighteenth 




few of them, including the great pharaoh, Ramses V.  They describe the appearance 
of lesions on the skin that resembled a smallpox rash [3].  This was the first physical 
evidence of smallpox ever found but written descriptions of the disease from this 
time, if any, remain to be discovered. 
 Over the centuries, smallpox spread around the world mostly by the exploring, 
colonizing, and the conquering of new land and continents. In places like Australia, 
North, and South America, the disease decimated native populations who had not 
previously been exposed to smallpox [3].  By the early 1900’s two types of VARV 
could be distinguished based upon one’s symptoms.  Along with the dreadful disease 
cause by VARV major, a milder version of the disease appeared.  The infecting virus 
causing the milder symptoms was referred to as variola minor.  In the unvaccinated, 
variola minor had less than a 1% case fatality rate while variola major had roughly 
30% case fatality.  
1.2.1.2 Variolation to Vaccination 
The earliest known practices to actively attempt at defending against smallpox 
disease was to quarantine individuals with smallpox or to practice a method now 
known as variolation.  Variolation was the technique of deliberate inoculation of 
dried scab or pustular material from a smallpox lesion to an uninfected individual in 
the hopes of obtaining a much less severe disease.  The two forms of variolation seem 
to have been developed independent of each other due to the different methods of 
inoculation.  One method of variolation arose in China around 1000 AD and consisted 
of a nasal route of inoculation by inhalation of the smallpox material.  The other 




of  inoculation [3].  The cutaneous route of variolation caused an even milder form of 
smallpox.  A primary lesion was formed at the inoculation site with commonly seen 
satellite pustules and a generalized rash.  Variolation by cutaneous route had a .5-2%
mortality rate.  The inhalation method for variolation was usually more severe and 
also produced a generalized rash.   
In the 18th century, variolation was a well established method for protection 
against smallpox.  However, the material used was not an attenuated version of 
VARV and a major disadvantage to variolation was that the virus could still cause 
and spread smallpox [3].  In the late 1700’s, Edward Jenner, an English physician, 
had many patients living in the countryside.  He would often perform variolation for 
his patients and in doing so he observed that dairy maids would not become infected 
after treatment.  He came to find out that these patients had contracted cowpox virus 
(CPXV) infections in the past.  This was interesting to Jenner and he eventually 
experimented with a young boy by inoculating the boy with CPXV material obtined 
from a milk-maid.  He  later challenged the boy with a smallpox inoculation of which 
had no ill effect on the boy [4].  Jenner performed additional trials and published his 
work on the successful use of cowpox at preventing smallpox.  He also published an 
account of his experience and the exciting possibility of smallpox eradication in the 
future [3-5]. 
Jenner’s vaccine provided many advantages and lowered risks over the 
practice of variolation and his vaccine was widely accepted all over Europe, the 
United States, and eventually around the world.  However, there were many problems 




the infection of cows was sporadic.  Initial arm-to-arm transfer of pustular material 
was a way to ensure the availability of virus but it was sometimes contaminated with 
VARV which could lead to smallpox.  This changed once smallpox hospitals were 
separated from places of vaccine preparation.  The arm-to-arm transfer wa  still a 
problem, though, as other human diseases were spread upon the vaccination of a new 
individual.  Additionally, it was quite difficult to maintain a series of individuals with 
pustules in which material could be used for further vaccination and often the virus 
used in arm-to-arm transfer was found to be less effective.  Sometimes the vaccine 
would be reintroduced into the cow, not as a source for obtaining more vaccine, but to 
reestablish the virulence of the vaccine.  Eventually the virus was produced on the 
flanks of calves and resuspended as a glycerol stock.  This practice helped to maintain 
the potency and availability of the vaccine as well as rid the possibility of transmitting 
other human diseases [3]. 
The more people vaccinated the less the incidence of smallpox and the lower 
the mortality rate when smallpox did reappear in a population.  Epidemics did occur 
and though less severe, eventually led to government interventions.  In some 
countries variolation was banned, vaccination was made compulsory for infants, and 
a scheme for revaccination was established.  In the late 1800s, the evolving of a 
scientific community gave rise to better methods for vaccine preparation and 
distribution. Endemic smallpox was virtually gone in both North America and Europe 





Unfortunately vaccine preparations of that time often had bacterial 
contamination.  It wasn’t until the early 20th century that scientists realized that it 
seemed more prudent that biological products used in man should be sterile.  Vaccine 
preparation and production continue to become safer and more efficient and the 
introduction of a liquid vaccine, which contained glycerol and phenol, aided in 
eliminating endemic smallpox from Europe and North America.  However, the liquid 
vaccine was not suitable for hot and tropical climates.  Finally, in the mid 20th 
century, a freeze dried vaccine that could be mass produced was made by Collier [3, 
6] and shown to be efficacious [7].   
In the 19th and beginning of the 20th century, before as well as during the time 
of vaccine development, material for vaccines was obtained as well as maintained in 
sheep, horses, cows, as well as arm-to-arm transfers.  There were plenty of 
opportunities for the different vaccine stocks used to become mixed or to obtain 
mutations after many transfers.  It appears that it was during this time that VACV also 
came into use as a vaccinating agent and was referred to as “vaccine virus.” Early 
literature describes vaccination with CPXV and it seemed that the virus being usd 
for some time had not been cowpox at all, but most likely some other orthopoxvirus 
[3].  The original source of VACV is still not known and, of course, there is much 
speculation as to its origin.  Two things are certain; vaccinia is a distinct 
orthopoxvirus and, like CPXV, provides a high degree of protection against smallpox. 
1.2.1.3 Smallpox Eradication 
In 1958, at the Eleventh World Health Organization (WHO) assembly, Viktor 




eradication of smallpox. All of the delegates agreed and a global eradication 
campaign began in 1959.  Over a period of seven years the eradication campaign had 
many problems.  It took a back seat to the malaria eradication campaign, it lacked
funding and execution, and there was little to no administrative oversight provided by 
the WHO.  It wasn’t until 1967 when the WHO started an intensified program with 
increased funds as well as implementation of the important concept of surveillanc  
[8].  The involvement of and commitment from the Communicable Disease Center 
(CDC) in the United States also influenced the outcome of the program [3]. 
At the conception of the intensified program, smallpox was endemic in Africa, 
Asia, Indonesia, and South America.  The global eradication initiative campaign 
strategy consisted of (i) mass vaccination and (ii) surveillance & containment.  Both 
of these strategies were necessary and within a 5 year time frame over 100 million 
vaccines were given.  The benefit of mass vaccination is that it provided herd 
immunity.  Eventually surveillance and containment became crucial for identifying 
and controlling outbreaks.  It consisted of searching for smallpox cases and 
vaccinating any and all contacts close to the infected individual [9]. The last naturally 
occurring case of smallpox was in Somalia, in 1977.  Finally, in 1980, Edward 
Jenner's prediction came true, smallpox was declared eradicated by the WHO.  
Many factors added to the success of ridding the world of such a devastating 
disease.  First, VARV is an obligate human pathogen with no known non-human 
reservoir.  If transmission from human-to-human was interrupted the disease could be 
eliminated.  Technical advances, like the bifurcated needle and freeze dried vaccine, 




smallpox cases and interrupt transmission was crucial to the eradication.  Importantly, 
an effective vaccine that led to years of protection in an individual also aided in the 
interruption of transmission.   
1.2.1.4 The Threat of Smallpox as a Biological Weapon 
The eradication of smallpox was a truly amazing feat and although it is almost 
30 years later, its reintroduction by way of a biological weapon is considered a 
possibility.  Following the smallpox eradication campaign there was a continuing 
debate over the deliberate destruction of all VARV stocks.  It was suggested by a 
WHO committee that all stocks of VARV either be transferred to 1 of 2 WHO 
appointed laboratories, either the Center for Disease Control in Atlanta, Georgia, or 
the Institute of Virus Preparations in Moscow, Russia [10].  All countries complied.  
There is, however, a first-hand account from a Russian defector, Ken Alibek, a 
former deputy director of the Soviet Union’s bio-weapons program, regarding a  
program that started in the USSR in 1980 to make and use smallpox as a biological 
weapon [11].  It is postulated that smallpox and the technology to grow it could have 
been acquired from the Soviet Union, during a time of financial need, by groups with 
ill will.  Of course, there also remains the possibility that some countries did not 
comply with the WHO and did not hand over all of their VARV stocks.  
There are a number of reasons to believe and anticipate the use of smallpox as 
a bioterrorist agent.   Its 30% fatality rate among unvaccinated individuals is one of 
the primary reasons it is considered a serious threat [10].  It cannot be denied that the
human population would be highly susceptible to the release of such an agent since 




most likely not help the non-vaccinated individuals.  Historical accounts of the 
introduction of smallpox to naïve populations are proof that it has been used in the 
past to successfully decimate large populations [3].  In addition to the fact that the 
virus particle is stable and easily transmitted via aerosol from person-to-pers n, most 
health care workers are not experienced in the diagnosis of human smallpox which 
could cause delay in determining the cause of illness.  There would also be confusion 
and eventually wide spread panic. 
With this and other threats in mind, the US signed into law Project Bioshield.  
Project Bioshield was enacted in 2004 in an effort to increase emergency 
preparedness in the United States against any major threat to the public.  Projet
Bioshield was designed to hasten research and development, secure funding to 
facilitate appropriate purchases, and aid in the development of convenient and useful 
approaches to protect against harmful agents and attacks [12].   
1.2.2 Monkeypox Virus and Cowpox Virus 
Monkeypox virus (MPXV) is a member of the orthopoxviruses and though 
initially discovered in 1958, it was not believed to be an important human pathogen 
until the early 1970’s [13].  Monkeypox is endemic in central and western Africa and 
mainly infects rodents and sometimes non-human primates [13-14].  Zoonotic human 
infections typically come about upon the intrusion of humans into tropical rainforests 
and possibly from children playing with contaminated carcasses.  The United Sta s
has also witnessed zoonotic episodes with  PXV in recent years due to the importat on 
of exotic animals from Africa [15-17].  Most zoonotic infections are acquired through 




inhalation [18].  Typically transmitted from animal to human, however, human-to-
human transmission has also been observed [19].  Zoonotic monkeypox infections are 
clinically indistinguishable from smallpox and though less fatal than a smallpox 
infection, there is no proven treatment for human monkeypox [15].  There is concern 
that monkeypox could become a more efficient human pathogen under favorable 
circumstances.  There are several reason to support this hypothesis:  the genetic 
makeup of the virus, the ecological changes, changes in host behavior, and routine 
smallpox vaccinations are no longer administered [14]. 
CPXV virus is another member of the orthopoxviruses best known for its use 
by Edward Jenner as the first vaccinating agent to smallpox.  CPXV was named for 
its isolation from lesions on infected cattle but the likely reservoir for this virus is 
wood mice or voles [20].  CPXV is distributed in Europe, Russia, the western states 
of the former USSR, and adjacent areas of northern and central Asia [21].  CPXV can 
cause a localized zoonotic infection; however, the occurrence for this is rare.  The 
virus is not often found in cattle and many of the zoonotic cases came about by 
contact with infected cats [22] and most recently in France from pet rats [21].  
1.2.3 Other Poxviruses that Cause Human Infection 
There are four poxviruses genera that can infect humans, exclusively or 
zoonotically:  Orthopoxvirus, Parapoxvirus, Molluscipoxvirus, and Yatapoxvirus 
[18].  Five members of the orthopoxviruses have been known to cause human 
infections. VARV, as previously discussed is strictly a human virus and causes the 
disease smallpox.  VARV has been eradicated from nature.  Also mentioned above, 




Buffalopox virus, another orthopoxvirus similar to VACV, causes a mild illness with 
few lesions on the hands and arms.  Its disease symptoms are similar to that of CPXV 
and though less severe it can leave minor pox-like scars.  The reservoir host is the 
water buffalo residing in India.  Human-to-human transmission to family members 
from those zoonotically infected has been reported [24].  
The genus Parapox has four members that are known to cause infection in 
humans, orf virus, pseudocowpox virus, bovine popular stomatitis, and seal 
parapoxvirus.  Human infection with a parapoxvirus is typically due to occupational 
hazard and seldom from fomites.  Orf virus is transmitted from sheep and goat, 
pseudocowpox virus is transmitted from dairy cattle, bovine popular stomatitis virus 
is transmitted from beef cattle and seal parapoxvirus is transmitted from seal and sea 
lion.  A human infection is acquired through a cut or scrape in the skin.  The virus 
then replicates locally in the regenerating keratinocytes and lesions come about by 
hypertrophy and proliferation of epidermal cells. Most human infections with 
parapoxviruses produce one lesion, which can resolve over a period of a few weeks 
[23]. 
Like VARV, molluscum contagiosum virus (MOCV) infections are restricted 
to humans and there is no evidence of transmission from humans to animals and no 
known animal reservoir.  Infection with MOCV is thought to be transmitted directly 
through a break in the skin though there are some cases where the virus has been 
transmitted by fomites.  Once the virus infects and replicates it initially forms a small 
papule which matures into a 2-to-5-mm smooth dome shaped nodule that appears 




located in the trunk and proximal extremities.  While lesions may only last for two 
months the infection can last for up to nine months [23].   
Two viruses belong to the Yatapoxvirus genus and both are able to cause 
infection in humans:  tanapox virus and yabapoxvirus.  The first recognized human 
infection with tanapox virus was first discovered in Kenya near the Tana River and is 
restricted to Africa.  Tanapox virus is not known to be transmitted from human-to-
human but there is evidence it may be transmitted by an insect vector.  Though rare, 
animal handlers have also contracted the virus directly from primates.  Once infect d 
with tanapox, a systemic infection ensues with fever, headache, and backache.  These 
symptoms diminish as the formation of the one typical lesion transpires.  Resolution 
takes approximately six weeks.   Yabapoxvirus is not a naturally occurring infectio  
in humans but causes infection if injected intradermally or subcutaneously [23].  
1.3 Vaccinia Virus 
The majority of research on orthopoxviruses has been carried out on VACV.  
It is a member of the orthopoxviruses and shares genetic and antigenic similarities 
with other orthopoxvirus members which is the reason VACV was effectively used as 
the vaccine to help rid the world of smallpox [1]. It continues to be used in the 
laboratory as a tool to understand the basic virological properties of the 
orthopoxviruses.  VACV is a convenient and safe alternative to the more pathogenic 





1.3.1 Structure:  Morphology and Composition 
There are two morphologically distinct infectious particles: the mature virion 
(MV) and the extracellular virion (EV) (Fig. 1).  Unlike most other viruses, the MVs 
are large and asymmetrical, and seemingly brick shaped with rounded edges.  The 
MV has a single lipid bi-layer containing irregular protrusions that encases a complex 
inner structure.  The core of the virion is electron dense, which is presumed to be 
DNA-protein complexes, dumbbell shaped and flanked by two lateral bodies of 
heterogeneous material.  It is approximately 360x270x250 nm in size and has an 
approximate mass of 9.5fg.  The virion is primarily protein, lipid, and DNA.  
Recently, a combination of cryo-microscopy and electron tomographic reconstruction 
was utilized to aid in determining the inner and outer structure of the MV, which is 
the most abundant particle form [25].  The EV is essentially an MV with an additional 
membrane derived from trans-Golgi or endosomal membrane [1].   
1.3.2 Genome Organization and Nomenclature 
 Poxvirus genomes are linear, double stranded DNA with covalently closed 
hairpin termini.  Poxvirus genomes range in size from 134 kBps (parapoxviruses) to 
300 kBps (avipoxviruses).  All poxviruses have inverted terminal repetitions (ITRs) at 
each end of their genome which are identical in sequence but opposite in orientation 
[26].  ITRs are not completely based paired as they contain the hairpin loops that join 
the two DNA strands [27].  Also within the ITRs are several open reading frames 
(ORFs), a series of variable length tandem repeats, and a highly conserved sequ nce 
of approximately 100 base pairs which is required for resolution of concatemeric 






Figure 1-1.  Morphological forms of infectious vaccinia virus. 
VACV infected cells were ultra-cryosectioned and viewed by transmission electron 
microscopy.  The arrows point to the single membrane in the image of the MV and 
the two membranes as well as the cell membrane in the image of the EV.  Image 




Poxvirus open reading frames (ORFs) are non-overlapping and tend to occur 
in blocks pointing toward the closer end of the genome.  Either an early, intermediate 
or late promoter sequence is present for each ORF.  The more highly conserved genes 
are located in the central region of the genome and tend to be involved in essential 
replication functions.  The more variable genes are found at the ends of the genome 
and tend to be involved in host-interactions.  The method of naming genes was 
adopted from the VACV strain Copenhagen before the full sequence of the virus was 
known and is based on the HindIII restriction digestion of the viral DNA.  Open 
reading frames are designated based on the size of the restriction fragment in which 
they are found, the largest fragment was designated A, and the smallest fr gment was 
designated P.  The letter of the fragment is then followed by the ORF number 
indicating the position in the fragment and an L (left) or R (right) to show the 
direction of the ORF (Fig. 2B).  The gene product is named similarly omitting the 
directional indicator.  Though other poxvirus genomes have been completely 
sequenced and genes numbered in successive order, this initial naming method was 
preserved to maintain consistency in the literature.  There are approximately 90 genes 
conserved in all chordopoxviruses with roughly half of those conserved in all 
Poxviridae [32].  
1.3.3 Viral Replication Cycle 
1.3.3.1 Attachment 
 Poxviruses have an elaborate life cycle (Fig. 3) complicated by the exist nce 






Figure 1-2.  Vaccinia virus genome organization.  A.  Depiction of the VACV 200 
kb double stranded DNA with inverted terminal repeats, hairpin loops, variable, and 
conserved regions.  B.  Depiction of VACV DNA fragments following digestion of 
the VACV genome with HindIII restriction enzyme.  Naming started with A through 








 the issue of attachment and entry is that VACV has a broad tropism making it quite 
difficult to identify a specific cell surface receptor.  The EV particle is involved in 
cell to cell spread and is essentially an MV particle with an additional outer 
membrane acquired during the wrapping process.  Most studies are done with the MV 
since it is stable, the more abundant form, and is easily purified.  Purification of the 
EV is also possible but the outer most membrane is quite fragile and can easily be 
disrupted.  The protein composition of the EV and MV membranes are different and 
this is the most likely reason for the difference in cell interactions.   
Another point is that MVs remain in the cell until lysis occurs, but EV is 
released from the cell and therefore the spread of VACV relies on EV particle.  Given 
that the proteins involved in VACV entry and fusion are found on the MV, the EV 
membrane must be removed or disrupted for entry of the MV to occur.  This 
disruption of the EV envelope involves two of the EV proteins, A34 and B5, and their  
interactions with cell surface polyanions [33].  Once the EV membrane is disrupted 
the MV particle is exposed to the cell surface allowing for MV-cell surface 
interactions to occur.  Three MV proteins A27, D8, and H3 [34-36] have been 
implicated in viral adsorption to the cell by binding cell surface glycosaminoglycans 
(GAGS).  A27 and H3 bind heparin sulfate while D8 binds chondroitin sulfate.  It is 
possible that these interactions may be a precursor to fusion, however, individually 
the proteins were not found to be essential for viral replication [37].  Another 
fascinating point is that MV can bind and enter Sog9 cells, which are deficient for 
GAGS.  Laminin may be important for binding since soluble laminin competitively 






Figure 1-3. Vaccinia virus life cycle.  Attachment occurs and MV particles fuse with 
the plasma or endosomal membrane.  Viral cores are released into the cytoplasm and 
early transcription begins.  Next the core is uncoated allowing for viral DNA
replication and concatemer formation.  Intermediate genes are then transcribed and 
translated allowing for late gene transcription and translation.  Morphogenesis begin  
with the formation of membrane structures called crescents.  Concatemeric DNA is 
resolved and packaged into the immature virions (IVs), which condense to form the 
intracellular MV. Most MV stay in the cell until lysis occurs.  Some MV are w apped 
by trans-Golgi network or early endosomal cisternae forming a wrapped virion (WV).  
The WV is transported to the periphery of the cell and WV fuses with the plasma 







 unable to infect resting T-cells but can infect activated T cells.  This could mean
resting T cells are deficient in cell specific factors that allow fr infection of activated 
T-cells [39]. 
1.3.3.2 Entry 
After attachment, most enveloped viruses either fuse with the plasma 
membrane or the membrane of an endocytic vesicle [40-41].  VACV, the prototype 
poxvirus, has been shown to utilize a few different strategies to enter cells.   VACV 
can fuse at the plasma membrane (Fig. 4), independent of pH [42], and some VACV 
strains can also enter certain cells lines via the endocytic pathway (Fig. 4) utilizing a 
low pH induced entry mechanism [43-44].  Additionally a recent report suggests 
VACV uses apoptotic mimicry and induces cell signaling so that entry of the virus 
occurs by macropinocytosis [45].  Lipid rafts have also been implicated in MV entry 
[46].  The MV particles fuse with the plasma membrane or the membrane of 
endocytic vesicles via a multi-protein fusion complex referred to as the entry-fusion 
complex (EFC) [47].  The EFC comprise at least 11 proteins: A16, A21, A28, G3, 
G9, H5, J5, L5, I2, and associated proteins F9 and L1 [48-56].  The EFC is not 
required for attachment which was demonstrated by the ability of EFC mutants to 
bind, but not enter cells.  The genes encoding the EFC proteins are conserved within 
all poxviruses suggesting the individual EFC proteins have non-redundant functions.  
It also suggests that the mechanism of entry had to have evolved before a division 






Figure 1-4.  Vaccinia virus entry mechanisms.  Immunoelectron microscopy was 
used to visualize MV fusing at the plasma membrane at neutral pH (left) and within 







1.3.3.3 Gene Expression 
 After fusion of the MV membrane with the plasma membrane, viral cores are 
found within the cytoplasm of host cells where they are transported on microtubules 
to the site of transcription [57].  There are three distinct temporal stages in VACV 
transcription, early, intermediate, and late, and each stage has a sequence specifi  
promoter found immediately upstream of each gene transcribed in that stage [58].  
The VACV genome is transcribed by a virus-encoded multi-subunit DNA-dependent 
RNA polymerase in union with early, intermediate, and late stage specific fators.  
The transcription factors for early gene expression are synthesized at late times in an 
infection and packaged in the virion.  The transcription factors needed for 
intermediate gene expression are synthesized at early times and the transcription 
factors needed for late gene expression are synthesized at intermediate times.  This 
mechanism, utilizing protein products from one stage of transcription to regulate the 
next stage of transcription, is referred to as a cascade mechanism of transcription.  
The cascade mechanism is used by many viruses to allow for the coordination of 
individual genes with specific processes, like DNA replication and virion assembly.   
VACV particles are packaged with a single copy of the genome and necessary 
transcription factors and enzymes for early stage of transcription which can 
synthesize mRNA that is capped, methylated, and polyadenylated [58].  The enzymes 
found within the particle that carry out early transcription include:  a multi-s bunit 
DNA-dependent RNA polymerase, RNA polymerase associated polypeptide of 




enzymes, poly A polymerase, nucleotide phosphohydrolase (NPH I), and 
topoisomerase I encoded by the gene D6L [1].   The viral RNA polymerase is a 
complex of 8 subunits:  RPO147encoded by the J6R gene, RPO132 encoded by the 
A24R gene, RPO35 encoded by the A29L gene, RPO30 encoded by the E4L gene, 
RPO22 encoded by the J4R gene, RPO19 encoded by the A5R gene, RPO18 encoded 
by the D7R gene, and RPO7 encoded by the G5.5R gene.  About 20-30% homology 
exists between the large viral subunits, RPO147 and RPO 132, and cellular RNA 
polymerases.  There is about 23% homology between RPO30 subunit and the 
eukaryotic transcription elongation factor SII.  RPO7 also shares about 23% amino 
acid homology with the smallest eukaryotic RNA polymerase subunit.  Unlike the 
core RNA polymerase subunits which are synthesized throughout the entire infectious 
cycle, RAP 94 (encoded by the gene H4L) is only synthesized at late times in 
infection and is exclusively involved in early mRNA synthesis [59].  VETF is a 
heterodimer encoded by the late transcribed D6R and A7L genes [60-61]. VETF 
directly interacts with the viral early promoter at the core region upstream and an 
additional, non-sequence specific, region downstream of the RNA start site [62].  The 
capping enzyme is a multifunctional heterodimer encoded by the VACV genes D1R 
and D12L. The cap is added to the nascent RNA approximately 30 nucleotides into 
transcription [63-66].  The cap structure is needed by the viral message for transport, 
stabilization, and recognition of the transcript by cellular ribosomes.  The capping 
enzyme is also required for transcriptional termination [67-68].  The poly (A) 
polymerase is encoded by the E1L gene (large subunit) and the J3R gene (small 




the small subunit acts as a processivity factor for the poly (A) polymerase [69].  
Intriguingly, the J3 protein methylates the capped end of the mRNA and is also 
involved in transcription elongation [70-73]. 
The early stage of transcription begins within the core soon after they gain 
access to the cytoplasm of the host cell.  Early promoters can be recognized by a 
single essential element consisting of a 16 base-pair core consensus sequence, 
AAAAgTaGAAAataTA, located -13 to -27 nucleotides upstream of the 
transcriptional start site flanked by a variable but highly A-T rich region.  A purine 
found 12 to 17 nucleotides downstream of the core sequence is where transcription 
initiation occurs [74].  VETF interacts with the early promoters and recruits the RNA 
polymerase to the initiation site to begin transcription.  VACV transcribes 
approximately half of the genes during the early stage of transcription [75-76].  Early 
mRNAs can be detected as early as 20 minutes post infection [58].  Early transcripts 
terminate approximately 20-50 base pairs downstream of the sequence TTTTTNT 
which is actually mediated by the RNA transcript sequence UUUUUNU [77-78].  
The early transcription termination signal is found at the end of most VACV early 
genes.  Two factors are required to induce termination and release of the transcript:  
NPH I and the capping enzyme. 
Since early mRNAs are synthesized within the core they have to be extruded 
out of the core and into the cytoplasm for translation [79-80].  Early mRNAs have 
been found in unique structures in the cytoplasm associated with microtubules and 




Along with the transcription factors and enzymes required for the intermediate 
stage of transcription, early stage gene products are also involved in DNA replication, 
such as the DNA polymerase, nucleoside triphosphatase, uracil DNA glycosylase, 
and the DNA polymerase processivity factor.  Many proteins involved in host 
interactions, such as immune modulation proteins, are also transcribed during the 
early stages of transcription. 
Intermediate genes are expressed after both uncoating of the core and viral 
DNA replication.  Inhibitors of DNA replication have been shown to block 
intermediate gene expression [82].  This suggests that a DNA templat  for 
intermediate transcription is unavailable to the newly synthesized enzymes and 
intermediate transcription factors.  The most obvious reason is that the infecting 
particle’s genome is sequestered within the core.  This idea is also supported by the 
study that when purified VACV DNA is transfected into infected cells it can serve as 
a template for intermediate and late transcription without the replication of the 
infecting viral DNA [82]. 
Intermediate stage promoters include two important regions, a 14-base paired 
core element and a 4 base paired initiator element.  The core and initiator element are 
separated by a 10-11 base pair region.  The necessary enzymes involved in 
intermediate stage transcription include:  novo synthesized viral RNA polymerase 
[83], viral capping enzyme (used for a mechanism other than capping) [63], VITF-1 
encoded by the E4L gene [84], VITF-3, a heterodimer of A8 and A23 [85], and  host 
cell encoded VITF-2 [86]. VITF-2 is a heterodimer of the cellular protein Ras-




Interestingly, a recent report shows intermediate transcription factors al ng with viral 
mRNA, cellular translational factors, and ribosomal proteins localizing to the viral 
factories suggesting viral transcription and translation is coordinated within the viral 
factories [88]. 
There are five known intermediately expressed genes, however, it is possible 
there may be others [89]. Three of the five intermediate expressed proteins are late 
stage transcription factors:  A1, A2, and G8 [82].  The other two intermediate genes, 
I8L and I3L, encode for the RNA helicase NPH II and the ssDNA binding protein, 
respectively.   
Late genes are expressed after intermediate genes and continue to be 
expressed until the end of the viral life cycle [90].   Late stage promoters include a 
20-base paired core sequence with some consecutive T or A residues, a 6 bp 
separator, and highly conserved initiator element with sequence TAAAT [91].  Often
the initiator element TAAAT is followed by a G to form TAAATG where the ATG, 
recognized in mRNA as AUG, serves as the site for translation initiation.  Enzymes 
involved in late stage transcription include:  the viral RNA polymerase, vaccini  late 
transcription factor (VLTF)-1 encoded by the G8R gene, VLTF-2 encoded by the 
A1L gene, VLTF-3 encoded by the A2L gene, and a host protein VLTF-X that 
consist of the heterogeneous nuclear ribonucleoproteins A2/B1 and RBM3 [92-93].  
The early expressed H5 protein, also known as VLTF-4, has been implicated in 
stimulating late transcription [94] and is also involved in elongation of late 




All of the VACV virus mRNAs are capped but in contrast to early mRNAs, 
intermediate and late mRNAs have a heterogeneous poly (A) leader sequence at the 
5’ end and both lack a defined 3’ end.  The 5’ heterogeneous leader is due to the 
slippage of the RNA polymerase while trying to initiate transcription [97-98].  There 
doesn’t appear to be specific intermediate and late transcriptional termination signals 
but a mechanism is likely and a few VACV proteins are seemingly involved:  A18, 
G2, and J3.    
 Late expressed proteins have quite an array of functions.  The structural 
proteins for both the EV and the MV are expressed late.  Many late proteins are 
required for virion morphogenesis and transport, and the early transcription 
machinery is expressed late and packaged in the virion.   
1.3.3.4 Uncoating 
Core uncoating and release of the genome into the cytoplasm is dependent 
upon transcription and translation of VACV early genes [99].  Disruption of the core 
coincides with the end of the early transcription stage and it is the early gene products 
that aid in core disassembly. This has been shown by the use of protein synthesis 
inhibitors during the early stages which results in increased and prolonged synthesis 
of early mRNA [100].  This proposes that when the core falls apart disruption of the 
early transcription machinery transpires [1]. 
1.3.3.5 DNA Replication 
VACV DNA replication occurs in the cytoplasm of their host cells.  These 
cytoplasmic foci of replication, coined “viral factories,” are found in the peri-nuclear 




Early mRNA transcription and translation is needed before DNA replication can 
occur since many factors involved in DNA replication are synthesized at early times 
in infection.  This accounts for the reason the purified viral DNA alone is non-
infectious.  There is still much to learn regarding VACV viral DNA replication as 
there are many gaps in the current model. 
DNA replication begins within one to two hours after cells are synchronously 
infected with VACV, though, the timing may vary with different poxviruses [1].  
Although attempts have been made to find a specific origin of replication, none have 
been successful.  It is thought that specific origin sequences reside at the ends of the 
genome, however, plasmid DNA lacking VACV sequence was able to replicate in 
cytoplasmic viral factories [103]. 
It is thought that the VAVC DNA replication utilizes a rolling hairpin strand 
displacement mechanism similar to that used by parvovirus [104].  Replication 
perhaps begins with a nick adjacent to one or both of the hairpin termini.  The nick 
presents the 3’ end for priming the replication complex which then synthesizes new 
DNA.  The newly synthesized DNA folds back on itself and the replication complex 
proceeds to synthesize the rest of the viral genome.  Large head-to-head and t il-to-
tail concatemeric structures arise during DNA replication and remain as so until after 
the onset of late transcription when unit length genomes are resolved by the viral 
Holliday junction resolvase encoded by the A22R gene [105]. This strand 
displacement mechanism is supported by the presence of ssDNA; however there ae 
reports of small DNA fragments covalently linked to RNA suggesting a lagging 




Replication of the VACV genome is dependent upon five virally encoded 
proteins:  DNA polymerase encoded by the E9L gene [107], a protein kinase encoded 
by the B1R gene, nucleic acid-independent nucleoside triphosphate encoded by the 
D5R gene [108], uracil DNA glycosylase encoded by the D4R gene [109], and a 
DNA processivity factor encoded by the A20R gene [110].  Attaining optimal levels 
of precursors for DNA metabolism is sometimes necessary and a variety of additional 
proteins are encoded by the orthopoxviruses for such activity.  The J2R gene encodes 
a thymidine kinase [111], the A48R gene encodes a thymidylate kinase [112], the I4L 
and F4L genes encode for a ribonucleotide reductase [113-114], and the F2L encodes 
for a dUTPase [115].   
1.3.3.6 Virion Assembly and Maturation 
 Assembly of the virus particle occurs after late stage transcription and m y 
of the late synthesized proteins partake in morphogenesis.  Many late stage proteins 
are also involved in early transcription and must be packaged in the particle during 
virion assembly.  In addition, the concatemeric DNA must also be resolved into unit 
length genomes for packaging, which requires the late expressed protein A22.  
Assembly of the virion is halted if unit length genomes are not processed [105].   
Electron microscopy (EM) was instrumental in providing the earliest evidence 
of viral assembly [116].  Assembly begins in the viral factory with the formation of 
membrane structures called crescents.  Studies with conditional lethal mutants 
revealed that late proteins F10 [117-118], H5 [119], G5 [120], and A11 [121] are all 
implicated in initial steps of crescent formation.  Interestingly, none of these proteins 




membrane and are also involved in membrane biogenesis are A14 and A17 [122-
123]. 
In EM images, crescent structures appear to be two layers with a single lipid 
bi-layer coated by regular spaced projections referred to as spicules.  It is the spicules 
that seem to provide the rigid arched shape to the crescents.  These spicules, which 
are actually trimers of the D13 protein[124], appear to form a honeycomb latticeas 
shown by deep etch EM [124-125].  It also appears that these single open lipid 
bilayers formed within the factories are without any connection to other cellular 
membranes and are presumably formed d  novo [126].  Later studies suggest that the 
crescent membranes are formed from the flattened membrane cisternae of the 
secretory pathway and therefore must be double membrane structures [127].  Freeze 
fracture studies are suggestive of a one lipid membrane model [125] and more 
recently that the membrane of crescents is derived from the endoplasmic reticulum 
and is not formed e novo [128].   
Crescents form around a dense area of the factory referred to as the viroplasm.  
The viroplasm is uniform, appears denser than the factories, and can be found as large
subdomains within the factories, called virosomes. The virosomes are often 
surrounded by many crescents that seem to take up portions of the virosome [129].  
Several core proteins have been shown to be involved in the interaction of the 
crescents with the viroplasm:  A15, A30, D2, D3, F10, G7, and J1 [130-134].  The 
crescents appear to grow in length and at the same time maintain the curvature 




nucleoprotein is inserted [135].  The core proteins, I6 and A32, and the membrane 
protein, A13, appear to be necessary for proper packaging of the DNA [136-138].    
After insertion of the nucleoprotein, crescents eventually evolve into the 
spherical IV.  This process can be blocked by the drug rifampicin [139] and mutants 
resistant to rifampicin were mapped to the D13L gene, whose gene product is 
responsible for the honeycomb lattice scaffold needed for assembly [140].  The 
appearance of the mature form of the virus (MV) follows after the formation of the
IV.  The important steps required for MV formation are not totally understood but 
involve assembly of the transcription apparatus, proteolytic processing of both core 
and membrane proteins [141-142], addition of several surface proteins, reorganizing 
of the particle to form a defined core and lateral bodies, and loss of the D13 scaffold.   
Assembly of the transcription apparatus is necessary for virion maturation as  shown 
by the formation of noninfectious virus particles when RAP94 is repressed [143], as 
well as by accumulation of IV when VETF is repressed [144-145]. 
Vaccinia encodes two proteins that have homology to known proteases, I7 and 
G1.  The proteolytic processing of both core (A17) and membrane proteins (A4, L10 
and L4) occurs most likely by the virally encoded I7 proteases.  I7  has been show to 
be important in formation of the MV since morphogenesis is blocked with a 
temperature sensitive mutant of  I7 [146].   Though G1 is not required for processing 
of the membrane or core proteins, conditional lethal mutants of G1 are also blocked 
in morphogenesis [147]. 
VACV encodes a complete pathway for protein disulfide bond formation  




system abrogates viral morphogenesis.  Several transmembrane proteins in the MV 
contain disulfide bonds in their cytoplasmic domain some of which are mediated by 
the VACV encoded disulfide bond pathway.   
The loss of the D13 scaffold is mediated by the proteolytic processed form of 
A17, a protein that has been shown to interact with D13.  A17 is processed by the 
viral protease, I7.  When I7 is repressed, disassembly of the D13 scaffold does not 
occur and aberrant virions are formed [149]. The addition of several surface proteins 
is seen after formation of MV from IV occurs and they include: A27, H3 [150], A26 
[151], and L1[152].  Four core proteins seem to be involved in the transition from IV 
to MV:  I1 [153], F17 [154], A4 [155], and A3 [156].  And three membrane proteins 
are known to be dispensable for IV formation but are required for MV formation:  A9 
[157], L1 [152], and H3 [150].   
1.3.3.7 WV Formation, Transport, EV Release, and Dissemination 
Most MVs stay in the cell until lysis occurs and typically localize in clusters 
within the cytoplasm of the infected cell.  Some MVs are transported on microtubules 
to be wrapped by virally modified trans-Golgi membrane or early endosomal 
membrane.  The acquisition of the two extra membranes around the MV is known as 
wrapping and results in the wrapped virion (WV) [158-159].  The WV has nine 
additional VACV expressed proteins:  A33, A34, A36, A56, B5, E2, F12, F13 and K2 
[160-168].  Wrapping of the MV requires several proteins and is inefficient in mutant 
viruses lacking A27 [169], B5[170], or F13 [171].  The WV is transported on 
microtubules to the periphery of the cell and the EV is exposed on the cell surface 




in the loss of the A36 and F12 proteins which are exclusively associated with the 
WV.  The EV displayed on the cell surface can induce the formation of actin tails.  
This mechanism is presumably used to push the particles away from the infectd c ll 
and toward the adjacent uninfected cell and mediate efficient cell-to-cel spr ad.   
1.3.4 Vaccinia Virus as a Tool 
One poxvirus phenomenon is the ability of viral genome to recombine.  
Homologous recombination can occur in cells infected with more than one virus or 
with a virus and other sub-genomic DNA [172].  Exploiting this mechanism to insert 
foreign genes makes VACV very attractive as an efficient expression ystem for 
many types of studies [173].   VACV has many advantages over other expression 
systems such as the ease of isolating recombinant viruses, the broad host range, the 
ability to insert large amounts of DNA, a high rate of protein expression, and its 
relative safety. 
Some examples include immunologic studies with immunogens such as that 
of herpes virus [174], hepatitis C [175], human immunodeficiency virus (HIV) [176-
177], and influenza virus [178-179].  VACV  is also quite useful in the large scale 
production of recombinant proteins [180].  VACV may also be used in gene therapy 
[181], in the treatment of some cancers [182], as a vector for rabies wild life vaccines 
[183]. 
1.4   Orthopoxvirus Pathogenesis 
 Pathogenesis is the mechanism involved in the production of disease, spread, 




immune response (discussed in the following section).  Different species within the 
orthopoxviruses as well as the different routes of entry can yield either a systemic or 
localized infection.  Details regarding VARV pathogenesis are inferred f om 
descriptions previous to the eradication of VARV as well as from animal models 
infected with other orthopoxviruses that produce a systemic infection similar to that 
produced by VARV.  Mousepox, the disease in mice caused by ectromelia virus 
(ECTV), is quite similar to the smallpox disease in humans.  The study of ECTV is a 
very good means towards understanding the pathogenesis of orthopoxviruses.  VACV 
is the prototype poxvirus and has been an excellent and safe tool for studying many 
aspects of orthopoxvirus pathogenesis. 
1.4.1 Variola Virus Pathogenesis 
It is thought that a naturally acquired VARV infection occurs after 
transmission of droplets from an infected individual reach the respiratory mucosa of 
an uninfected individual [23].  The dose required to establish a primary infection is 
believed to be just a few virions [10].  The virus migrates to the regional lymph nodes
and is amplified.  Three to four days post infection an asymptomatic viremia ensues 
followed by a latent period of 7-17 days in which the virus continues to replicate.  
Another phase of viremia occurs and is followed by the prodromal phase.  The 
prodromal phase is the first phase of symptoms and lasts approximately 2-4 days.  
Prodromal symptoms include malaise, headache, backache, fever, vomiting, and 
muscle pain.  Mucous membrane lesions, caused by the localization of virus within 
the small blood vessels of the dermis and oral/pharyngeal mucosa, appear before the 




until the appearance of lesions within the mouth.  Lesions evolve into macules, first 
on the face followed by all parts of the body within 24 hours.  Macules turn into 
raised papules by the 2nd or 3rd day.  Papules turn into vesicles which form pustules.  
Formation of pustules coincides with another phase of fever.  Eventually crusts form 
over all of the lesions.  Crusts eventually fall off and the skin is left with depigmented 
pitted scar.   If the infection is fatal, death typically occurs between the 10th and 16th 
day.   Both, variola major and variola minor, cause smallpox.  Variola major exhibits 
a more severe form of disease with a case fatality rate of about 30%.  Variola minor 
tends exhibit a less severe disease with a mortality rate of ~1% [3, 10, 184].  
1.4.3 Ectromelia Virus Pathogenesis 
 ECTV was identified in an infected laboratory-mouse colony in 1930.  
Additional strains have been isolated since then with different disease severities 
[185].  Epidemiologic studies suggest that ECTV is transmitted by abrasions in the 
skin from infected animals or fomites [186].  This mode of transmission can be easily 
imitated by infecting via the footpad.  The virus replicates at the site of entry in the 
epidermis.  Virus then migrates and replicates in the local lymph nodes and primary 
viremia is established.  Viremia allows the virus to reach and replicate in th  spleen, 
liver, and other organs.  A second viremia develops when replicated virus is release
into the blood stream from the infected organs.  Secondary viremia leads to the 
infection of the skin, distal to the primary infection which typically becomes inflamed 
due to the immune response.  Infection with certain strains of ECTV can also lead t




1.4.2 Vaccinia Virus Pathogenesis 
The VACV vaccine is given with a bifurcated needle and currently only given 
to those working with orthopoxviruses in research labs, public health care workers, or 
to  U. S. military personnel [187].  In August 2007, ACAM 2000, the current 
smallpox vaccine, was licensed for use in the United States by the Food and Drug 
Administration.  The vaccine is live VACV and replicates immediately at the primary 
site of infection.  A red papule appears at the vaccination site 3-5 days after 
vaccination.  The papule turns into a pustule and typically reaches it maximum size 
by day 10.  The pustule eventually dries and crusts over.  Crusts eventually separate 
14-21 days after vaccination.  The infection remains localized and often regional 
lymphadenopathy and fever will occur [188]. 
There are complications that sometimes arise after a vaccination.  These 
include:  progressive vaccinia, generalized vaccinia, post vaccination 
encephalomyelitis, eczema vaccinatum, and accidental infection [23].  Progressive 
vaccinia is rare and occurs in persons with severe cell immunity deficiencies.  
Progressive vaccinia is the growth and spread of the virus beyond the site of 
inoculation and is usually fatal.  Generalized vaccinia is the appearance of a pustular 
rash and there is no known predisposition to attain this rare reaction.  Post vaccination 
encephalomyelitis seems to occur by direct viral invasion of the nervous system or it 
is possibly post-immunization demyelinating encephalomyelitis.  It is a rare 
complication and again there are no predisposing factors known.  Eczema vaccinatum 
occurs in those with a history of eczema, also known as atopic dermatitis.  After 




general rash appears.  Accidental infection happens when a vaccinated individual 
transmits the virus to an additional site on themselves or to another individual. 
1.5 The Innate Immune Response to a Viral Infection 
 The innate immune response plays a critical role in the host response to a viral 
infection.  It is the initial, fast acting, non-specific response that detects and keeps an 
infection in check until the adaptive (specific) response can kick in and help clear the 
infection from the host.  The major players of the innate immune response to a viral 
infection include:  apoptosis, pattern recognition receptors (PRR), natural killer (NK) 
cells, plasmatoid dendritic cells, macrophages, neutrophils, complement, RNA 
interference (RNAi) and various cytokines released by cells including the pro-
inflammatory cytokines, chemokines, interferon (IFN), and tumor necrosis factor-α 
(TNF-α).  
1.5.1 Apoptosis 
Apoptosis is the process of programmed cell death and is a tightly regulated 
intrinsic cellular mechanism involved in maintaining homeostasis, cell developm nt 
and differentiation, and detection and protection from invading pathogens.  Its 
description is included in this section since virally infected cells can trigger a variety 
of signals leading to apoptosis.  Apoptosis can be triggered by both external and 
internal stimuli such as TNF or DNA damage, respectively (Fig. 1-5).  Cellular 
recognition of these stimuli results in a signal transduction which activates a s t of 






Figure 1-5.  Apoptotic pathways.  (A) The extrinsic pathway is induced by death 
receptor signaling when cytokines (e.g., TNF or Fas ligand) bind to death receptors. 
This leads to the activation of caspase-8 which leads to the sequential activation of 
effector caspases, 3, 6 & 7, and ultimate cell death.  (B) The intrinsic pathway is 
controlled by B-cell lymphoma protein-2 (Bcl-2) family members. The intrinsic 
pathway is stimulated by cell stress and results in loss of mitochondrial membrane 
integrity, release of cytochrome, formation of the apoptosome, activation of caspase 
9, activation of effector caspases 3, 6, &7, and ultimate cell death.  Figures adapted 









select set of cellular target proteins; this proteolytic cleavage can either inactivate or 
activate a target protein by cleaving off regulatory domains [189].  Two well studied 
extrinsic pathways are Fas- and TNF-receptor induced apoptosis.  These plasma
membrane receptors have death effector domains (DEDs) found in their cytoplasmic 
region.  Binding of their appropriate ligands initiates a signal transduction begi ning 
with the recruitment of cytoplasmic adapter proteins that also contain DEDs which in 
turn leads to the recruitment and activation of pro-caspase-8.  Caspase-8 cleaves and 
activates pro-caspase-3, -6, and -7.  These effector caspases proteolytically cleave 
target proteins responsible for the execution of the cell [189].  The extrinsic pathway 
can also indirectly involve the mitochondria (MT) and its permeabilization, a step 
involved in cell death.  The intrinsic pathway directly involves the MT and its 
permeabilization and ultimate release of pro-apoptotic factors that normally localize 
to the MT.  The Bcl-2 proteins regulate mitochondrial membrane permeabilization 
(MMP) either by inhibition or promotion; Bcl-2 proteins can be pro- or anti-apoptotic 
[190].  Another pro-apoptotic protein released from the MT due to the change in 
MMP is cytochrome c (cyt c).  When released from the MT, cyt c interac s with Apaf-
1 and pro-caspase 9 which in turn triggers the activation of caspase-9.  Caspase-9 can 
then initiate apoptosis by cleavage of the effector caspases -3, -6, and -7 [189]. 
1.5.2 Pattern Recognition Receptors 
PRRs are a group of receptors found on the cell surface, in cellular 
compartments, as well as within the cytoplasm of the cell.  They are involved in the 
early detection of a viral infection by recognizing certain pathogen associted 




are evolutionarily conserved, membrane bound PRRs that recognize many different 
PAMPs such as dsRNA, CpG DNA, and other pathogen associated motifs found on 
or as a product of viruses [191].  Many viruses enter cells via the endocytic pathway 
therefore it is not surprising that many TLRs involved in viral recognition are found 
in the endosome such as TLR3, TLR7, TLF8, and TLR9 [192].  TLRs have an 
intracellular TIR (Toll/IL-1 receptor) domain which is a motif present in the TLR
superfamily of receptors.  These receptors are key to innate immunity and 
inflammation.  Retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) are 
cytoplasmic PRRs that include RIG-I and melanoma differentiation-associ ted gene 5 
(MDA5) [193] and recognize viral nucleic acids [194-195].  Upon binding of their 
PAMP, PRRs initiate intracellular signaling through the recruitment of one or many 
adapter molecules which then culminates in the activation of transcription fact rs NF-
κB, IRF3, and IRF7 (Fig. 1-6).  These transcription factors induce both Type 1 IFN 
and pro-inflammatory cytokine production. 
Recently cytosolic DNA-sensing systems have been identified and the 
proteins directly involved in sensing DNA are known as DAI (DNA activator of 
IRFs) and AIM2 (absent in melanoma 2).  DAI upregulates Type-1 IFN and activates 
NF-κB while AIM2 activates caspase-1 and NF-κB [196-199]. 
1.5.3 Cells of the Innate Immune Response 
NK cells are large granular lymphocytes that patrol blood and lymphoid tissue 
and provide potent anti-viral activity.  They comprise about 20% of all circulating 
lymphocytes and that number increases upon detection of a viral infection until the 





Figure 1-6.  Examples of pattern recognition signaling.  Signaling 
pathways via (A) TLR-3, (B) TLR-7 or -9, and (C) RLRs, MDA5 and RIG-1. Figure 




distinguish whether they should destroy their target cells or not:  an activation 
receptor and an inhibition receptor [200].  Though the mechanism is not completely 
understood, virus infected cells are recognized by the activation receptor.  Once the 
receptor binds to an infected cell the NK cell kills the infected target cell.  It does so 
by using granzymes and perforins, which perforate the membrane of the infected cell 
inducing cell death.  This outcome is only true if the inhibitory receptor is not co-
stimulated when the activation receptor is stimulated.  The inhibitory receptor is 
provided as MHC class I and its presence or absence dominates the fate of the cell.  If 
MHC class I is downregulated on the target cell then the NK cell will kill its target.  
However, the NK cell will still only be stimulated if the activation receptor binds to 
its ligand since inhibition dominates over activation.  NK cells are also known to 
release cytokines to add to the inflammatory response (Fig. 1-7) 
 Dendritic cells are sentinel cells that reside in the skin and mucosal 
membranes.  They have PRRs as well as receptors that bind the cytokines released 
from infected cells.  They in turn release large amounts of cytokines (primarily Type-
1 IFN) to help combat a viral infection.  They are also involved in antigen 
presentation which activates the adaptive immune response. There are two subsets of 
dendritic cells, plasmacytoid dendritic cells and myeloid dendritic cells, each 
recognizing different pathogens via their distinct set of receptors and each inducing 
different types of immune responses depending on the existing extracellular 
environment [201].  Plasmacytoid dendritic cells (pDC) are immature dendritic cells 






Figure 1-7.  Mechanism of NK cell activation or inhibition.  (A) Inhibition of NK 
cell kill signal due to recognition of self MHC class I.  (B) Activation of NKcell 
signal since the inhibitory receptor is not stimulated but the activation receptor is 
stimulated by binding to its ligand. NK cell responds by releasing granules 
responsible for cytotoxicity of target cell. Figure from French and Yokoyama, 






large amounts of Type I IFN as well as pro-inflammatory cytokines, TNF-α and IL-6, 
in response to a viral infection.  pDC have a role in both the innate and adaptive 
immune response since they mature into potent antigen presenting cells. 
 Monocytes and macrophages are a significant source of a variety of soluble 
immune mediators, including cytokines and chemokines. Along with the possibility 
of differentiating into dendritic cells, monocytes can also differentiate into 
macrophages.  Macrophages and neutrophils respond to chemotactic signals and are 
involved in the inflammatory response.  Both macrophages and neutrophils are the 
main phagocytic cells during an immune response to a viral infection and remove 
dead, damaged, and infected cells [202].  
1.5.4 The Complement System 
The complement system is a significant mediator of the innate as well as the
adaptive immune response to a viral infection.  Complement consists of a family of 
approximately 30 serum and membrane proteins.  These proteins work in a sequential 
fashion to target and destroy bacteria, viruses, and infected cells.  Thereare three 
complement pathways:  the classical, the alternative, and the lectin-binding pathway 
(Fig. 1-8).  The classical pathway is activated by the initial binding of C1q (either to 
antibody-antigen complexes or to pathogen surfaces) and the subsequent formation of 
the C1 protein complex (C1qr2s2). The C1 protein complex cleaves complement 
components C4 and C2 into C4a & C4b and C2a & C2b.  C4b and C2a bind to each 
other to form the classical pathway C3-convertase (C4b2a complex).  C3-convertase 






Figure 1-8. Complement pathways.  Activation of the complement system via the 
classical pathway (CP), the lectin pathway (LP), or the alternative pathway (AP).  C3 
convertases cleave C3 to C3a and C3b.  Accumulation of C3b leads to the assembly 
of C5 convertases which cleave C5 to C5a and C5b. C5b initiates the formation of the 
lytic membrane-attack complex (MAC).  The MAC is comprised of the complement 
components:  C5b, C6, C7, C8 and C9. C3a and C5a induce pro-inflammatory and 
chemotactic responses by binding to their receptors. Figure from Lambris et all, 








 of inflammation while C3b is the primary effector protein for all three compleent 
pathways.  C3b remains attached to an infected cell or invading pathogen where it 
recruits additional components of complement that eventually form a channel in th  
membrane known as the membrane attack complex (MAC).  The MAC is comprised 
of the complement components:  C5b, C6, C7, C8, and C9.  C5 is first recruited to the 
surface and cleaved into C5a and C5b by the complex C4b2a3b (C5 convertase).  C6 
and C7 bind to C5b and with recruitment of C8 they form a small hydrophobic 
complex which inserts into the membrane as a small pore.  C9 interacts with the 
C5b678 complex and expands the pore.  This perturbation of the membrane typically 
results in death of the microbe or infected cell due to osmotic lysis.  
In the alternative complement pathway C3 is spontaneously cleaved to C3a 
and C3b.  C3b can then bind to the membrane of an infected cell or pathogen.  Bound 
C3b interacts with complement component factor B to form C3bB. In the presence of 
complement factor D, C3bB will be cleaved into Ba and Bb.  C3b binds to Bb to form 
C3bBb, the alternative pathway C3-convertase.  In the lectin-binding pathway, a 
protein similar to C1q starts the cascade when bound to mannose residues.  This 
mannose binding lectin is a PRR and belongs to the family of collectin proteins.  
Collectins bind polysaccharides found on many different microbes including many 
enveloped viruses.   
1.5.5 RNA Interference 
RNAi is a significant contributor to the innate defense against virus infection.  
The RNAi pathway can act via endogenous micro RNAs (miRNA) or via small 





Figure 1-9.  RNAi pathways. The siRNA pathway utilizes the enzyme Dicer to 
cleave long double stranded RNA (dsRNA) into siRNA. The siRNAs generated after 
cleavage are incorporated into AGO2 and RISC.  AGO2 cleaves the sense strand 
leaving RISC with the antisense strand which recognizes target sites to direct mRNA 
cleavage.  In the microRNA pathway, primary microRNA (pri-miRNAs) are 
transcribed by RNA Pol II and processed by the enzyme Drosha to yield pre-miRNAs 
which are exported to the cytoplasm by exportin 5.  Dicer binds and processes pre-
miRNA which is then loaded onto the AGO2–RISC complex as a mature miRNA.  
The miRNA recognizes target sites in mRNA which leads to translational inhibition 





double-stranded RNA (dsRNA) into short 21-24 nucleotide fragments referred to as 
siRNA (or viRNA when derived from a virus) by the enzyme Dicer.  The siRNAs are 
loaded into an Argonaute 2 (AGO2) containing RNAi-induced silencing complex 
(RISC) and one strand of the RNA is cleaved and degraded.  The remaining siRNA 
strand recognizes and binds target sites on mRNA to direct cleavage by AGO2 thus 
inhibiting translation [203-204].  miRNAs are encoded by the host cells RNA 
polymerase as primary miRNA transcripts (pri-miRNAs).  Pri-miRNAs are processed 
by the enzyme Drosha to yield short stem loop precursor miRNAs (pre-miRNAs).  
pre-miRNAs are exported to the cytoplasm and processed by Dicer to form miRNA.  
Similar to siRNA, miRNA is loaded onto the AGO2–RISC complex where the 
passenger (sense) strand is lost. The mature miRNA, bound to active RISC, can 
recognize target sites in mRNA and direct translational inhibition by binding of 
miRNA to target mRNA, which leads to translation repression and possibly to mRNA 
degradation [203-204].  The RNAi pathway acts directly on viral RNA to inhibit 
translation of viral proteins and since host miRNAs do not have to rely on complete 
base pairing they also act indirectly to target viral RNA and inhibit translation.   
1.5.6 Cytokines, Chemokines, and Interferon 
Cytokines are soluble products secreted from many different cells and are 
mediators of cell communication.  They are absolutely critical in the host immune 
response to a viral infection since they are immediate players upon a viral infection 
and can control inflammation, induce an antiviral state, and regulate the action of the 
adaptive immune response.  An infected cell will produce and release cytokines that 




and macrophages. The binding of these cytokines results in the synthesis and release 
of more cytokines from the uninfected cells and a continuous amplification of the 
initial response to infection transpires.  Many cytokines, such as IFN, are pleiotropic 
and are influenced by the concentration as well as the other cytokines present in th  
surrounding milieu.  Tumor necrosis factor-α (TNF-α) is a cytokine released from 
activated monocytes and macrophages.  Along with its involvement in apoptosis, 
TNF is also involved in inflammation.  Other important pro-inflammatory cytokines 
include IL-1 and IL-6.   
Chemokines are chemotactic cytokines which are important for guiding 
leukocytes to the sites of infection [205].  Chemokines bind to glycosaminoglycans 
(gags) on the surface of cells and establish a concentration gradient which aids in the 
activation and chemotaxis of leukocytes and macrophages.  The attracted cells mov  
through the gradient to the higher chemokine concentrations. 
IFNs are critical cytokines in the initial response to a viral infection.  There 
are three classes of IFN:  Type I (e.g. IFN-α, IFN-β), Type II (e.g. IFN-γ) and Type 
III (IFN-λ1, - λ2, - λ3) [206].  Type I IFN is the first cytokine to emerge in high 
concentrations upon a viral infection.  It can be made by all nucleated cells and can be
induced as easily as a virion binding to a cell [207].  Type II IFN is exclusively 
secreted by T-cells and NK cells.  When secreted, IFN binds to an appropriate 
receptor on nearby cells and induces a signal transduction through the JAK/STAT 
pathway (Fig. 1-10) which culminates in the upregulation of hundreds of  genes 





Figure 1-10.  IFN signaling pathways.  IFN-α/β bind the Type-1 IFN receptor 
which is composed of two subunits.  The subunits, IFNAR1 and IFNAR2, associate 
with TYK2 (tyrosine kinase 2) and JAK1 (Janus activated kinase 1), respectively.  
IFN-γ binds a separate receptor, also composed of two subunits, IFNGR1 and 
IFNGR2, which associate with JAK1 and JAK2, respectively.  Binding of IFN to 
appropriate receptor leads to TYK and JAK phosphorylation which in turn leads to 
recruitment and phosphorylation of STAT proteins.  Once phosphorylated, STATs 
dimerize, enter the nucleus, and bind to transcriptional control sequences such as 
ISRE (IFN stimulated response elements) and GAS (gamma-activated site). Figure 




of these ISGs act directly on the viral life cycle or add to the host’s ability to detect 
virus.  The upregulation of ISGs can lead to an antiviral state, in which cells ar  much 
more resistant to a viral infection.  IFN can also induce apoptosis as well as activ te 
both NK and dendritic cells [208-209].   
Often cells halt protein synthesis of both viral and cellular mRNA upon viral 
infection.  Frequently, this defense mechanism is mediated by the upregulation of the 
ISG, double stranded RNA-activated protein kinase (PKR).   Inactive PKR is a 
serine/threonine kinase that is normally present in the cell in low concentratio s.  
Higher concentrations of inactive PKR appear after IFN binds its receptor on an 
uninfected cell.  PKR will subsequently become active upon binding dsRNA in an 
infected cell.  While bound to dsRNA, activated PKR phosphorylates eIF-2α.  The 
phosphorylated form of eIF-2α binds eIF2B, a protein involved in the catalytic 
recycling of eIF2-GDP to eIF2-GTP.  eIF2-GTP is necessary for translation initiation.  
Phosphorylated eIF-2α has a high affinity for eIF2B and once bound, eIF-2α 
sequesters eIF2B from recycling eIF2-GTP ultimately inhibiting translation.  
Another upregulated ISG defense mechanism used to prevent synthesis of 
both viral and cellular proteins by degradation of cellular and viral RNA is the RNase 
L and 2’-5’ oligo (A) synthetase.  Some examples of other important ISGs include the 
Mx family of genes, promyelocytic leukemia (PML) nuclear bodies, APOBECs and 
Trims, adenosine deaminases, viperin, miRNAs, IFN regulatory proteins (IRFs), and 
Nitric oxide synthase.  Although many ISGs have been well studied there are many 







Figure 1-11.  Activation of NF-κB. NF-κB is found in the cytoplasm of cells bound 
to IκBα which renders the transcription factor inactive. A variety of extracellular 
signals activate IKK, which, in turn, phosphorylates the IκBα protein.  Once 
phosphorylated, IκBα is ubiquitinated and degraded in the proteasome. Activated NF-





NF-κB is a key, rapid-acting, transcription factor involved in many pathways 
induced upon a viral infection.  It contributes to inflammation and is involved in the 
induction of IFN.  NF-κB resides in the cytoplasm of cells bound to IκBα which 
renders it inactive.  Activation of NF-κB occurs once IκBα becomes phosphorylated 
and subsequently ubiquitinated and degraded by the proteasome.   Activated NF-κB 
translocates into the nucleus of cells and the induction of many antiviral genes ensues.  
IκBα phosphorylation is mediated by the activated IKappaB kinase protein (IKK).  
Viruses stimulate cells to induce many signal transduction pathways that culminate in 
the activation of IKK, ultimate degradation of IκBα, and translocation of NF-κB into 
the nucleus of the cell (Fig 1-11). 
My discussion has primarily focused on the innate response to a viral infection 
since most VACV immune modulators target those initial fast acting host reactions.  
It is important to mention that both arms of the immune response, innate and 
acquired, are required for full viral clearance.  VACV genes directly modulating the 
adaptive immune response have yet to be discovered. 
1.6 Viral Virulence 
 The virulence of a virus is measured by the ability of that virus to cause 
disease.   The objective to researching viral virulence is to find and understand 
mechanistically how viral and cellular genes contribute to virulence.  Findings ca  
possibly lead to attenuated strains for vaccine use or targets for drug therapies.  Many 
factors can affect the virulence of a virus including inoculation dose, route of 




Viral virulence can involve one or a combination of many different gene 
products.   There are gene products that are toxic to the host, aid in viral spread in and 
among hosts, increase the replication of the virus within the host, or modulate the 
immune response of the host [207].   Modification of intrinsically toxic gene products 
typically results in diminished viral virulence in both cell culture and animal hosts.  
Genes needed for the virus to spread within the host may not always be apparent.  For 
example, a virus carrying a mutant gene involved in spread within the host may 
appear normal in cell culture but the same virus may not be able to disseminate to its 
target organ(s) within the host.  There are genes that can also affect both viral 
replication and viral virulence.  There are two categories for these types of genes.  
First, there are the viral mutants that exhibit very low to no replication in vivo or cell 
culture.  These mutants typically are unable to produce enough virus to cause disea
which means virulence is reduced.  Second, there are viral mutants whose replication 
is not hindered in cell culture, however, the virus is unable to replicate and cause 
disease in an animal host.   The latter is an example of genes that are of great inte est 
as they represent the genes that specifically cause disease.   
In order for a virus to survive and replicate in a host it must be able to counter 
the vigorous host immune response.  Many viruses have evolved anti-immune 
mechanisms that enable them to be successful pathogens and survive in the hostile 
environment of their host.  These anti-immune mechanisms utilize viral gene products 
that are expressed as receptors either on cell surfaces or virion surfaces (viroceptors), 
expressed and secreted from infected cells (virokines), or are expressed 





Table 1-1.  VACV virulence genes with known functions.  
 
Gene Time of 
Expression 
Localization Function 
B13R Early Intracellular Inhibits apoptosis by preventing cleavage of Caspase-1 
(ICE) 
F1L Early Mitochondrial Inhibits apoptosis by interfering with release of 
cytochrome C 
N1L Early/Late Intracellular Inhibits apoptosis and  NFκB activation 




Intracellular Inhibits TLR signaling by interrupting interaction 
between IRAK and TRAF6 
C21L Predicted late Secreted Complement control protein; inhibits classical and 
alternative pathways 
C12L Early Secreted IL-18 binding protein decoy 
B15R Predicted Late Secreted Soluble IL-1β receptor decoy 
A41L Early Secreted Binds and inhibits CC chemokines 
B8R Early Secreted IFN-γ receptor decoy 
B18R Early Soluble/Cell 
Surface 
IFN-α/β receptor decoy 
E3L Early Intracellular dsRNA bp - prevents activation of IFN induced PKR 
K3L Early Intracellular PKR bp - prevents PKR auto-phosphorylation 
K1L Early Intracellular Prevents IκBα degradation thus inhibiting NFκB 
activation 
B14R Early Intracellular Inhibits  NFκB activation by preventing IKK activity 
M2L Early Intracellular Inhibits NFκB activation via ERK2 phosphorylation 




immune response.  Discussed below are some examples of VACV proteins involved 
in host immune modulation.  For a brief description refer to Table 1-1. 
All of the proteins described below contribute individually to virulence 
suggesting they are not functionally redundant.  There are many cellular lines of 
attack to fight an invading pathogen and VACV has found many offensive strategies 
to escape, mitigate, and manipulate these host defenses.   
1.6.1 Apoptosis Deterrents 
The VACV B13R gene was originally investigated due to the sequence 
similarity of the B13R gene product with the serine protease inhibitor (serpin ) 
superfamily of proteins.  B13, also referred to as SPI-2, is an early expressed and 
stable intracellular protein.  A B13R deletion virus grew similarly to the wild type 
and revertant virus controls in cell culture.  Additionally, there was no attenuation 
observed when infecting mice with a B13R null virus in an intranasal (IN) model of 
infection [211].  Continued work on the B13R gene led to the finding that B13 
inhibits Caspase-1, also known as ICE (Interleukin 1 Converting Enzyme), which 
functions in apoptosis as well as cleaves precursor forms of IL-1β into its mature 
form.  IL-1β is an inflammatory cytokine and contributes to the febrile response in the 
host.  In spite of the Caspase-1 inhibition, B13 did not prevent fever in infected mice, 
however, B13 did inhibit both  Fas- and TNF-induced apoptosis [212].   
VACV has also been shown to inhibit mitochondrial induced apoptosis [213], 
however, the virus does not encode a BCL-2 homolog which made it difficult to 
determine the gene responsible for this function.  Initial work to find the VACV F1L 




virus VV811 [214].  VV811 is a mutant of the Copenhagen (Cop) strain of VACV 
that happens to be missing 55 ORFs from both the left and right termini of the 
genome.   Infection of cells with VV811 activates the apoptotic pathway, a condition 
not seen in cells infected with the wild type VACV Cop.  To determine the gen 
responsible for apoptosis, ORFs carrying genes missing from the VV811 virus were 
transfected into VV811 infected cells. The ORF F1L was able to restore the apoptosis 
inhibition phenotype.  Additional studies found that the F1 protein localizes to the 
MT and that it inhibits mitochondrial induced apoptosis by inhibiting the loss of 
MMP and interfering with the release of cyt c [214]. 
The N1L gene product is multi-functional protein and is not only involved in 
inhibiting apoptosis but also inhibits the NF-κB pathway (discussed below).   N1 is 
one of the genes missing from a 17 gene deletion in the mutant VACV WR 6/2 [215].  
The virus WR 6/2 grows normally in cell culture but is attenuated in vivo [216].  To 
determine if N1 was a contributing factor in the attenuation of VACV WR 6/2 the 
N1L ORF alone was disrupted in the parental WR virus and tested for virulence in 
follow up mouse studies.  The studies revealed that N1 was a contributory factor to 
virulence [217-218].  Although the N1 protein has no cellular homolog the crystal 
structure of the protein reveals a similarity to BCL-2 proteins and it was able to co-
precipitate with pro-apoptotic BCL-2 proteins: Bid, Bad, and Bax and was also shown 
to inhibit staurosporine-induced apoptosis [219].   
1.6.2 Interruption of Pattern Recognition Receptor Signaling 
VACV encodes two proteins that interfere with TLR signaling and contribute 




share amino acid sequence identity with the TIR domain of the TLR /IL-1 receptor 
superfamily of receptors.  Both proteins were also shown to interfere with IL-1signal 
transduction.  A46 interfered partially with induction of NFκB while A52 effectively 
blocked IL-1 and TLR4 activation of NFκB [220].  Later studies of A46 showed that 
A46 targets multiple host cell TIR adapter molecules and inhibits intracellular 
signaling by many TLRs.  VACV mutants lacking the A46R gene were attenua d in 
murine IN infections [221].  These studies demonstrate that A46 is important for 
VACV virulence.  Additional studies concerning A52R show that the A52 protein 
associates with IRAK2 and TRAF6 and disrupts interactions between these two 
important proteins which are involved in the TLR signaling pathway.  In addition, 
VACV mutants lacking the A52R gene were also attenuated also in a murine IN 
infection [222].   
1.6.3 The Classical and Alternative Complement Cascade Curtailed 
 Initially, the VACV C21 protein was found as an abundant polypeptide 
secreted from infected cells and had amino acid similarity to the human C4b binding 
protein, which belongs to the superfamily of complement control proteins and binds 
the C4b complement protein [223].  Medium from cells infected with a recombinant 
VACV lacking the C21L gene was unable to inhibit cell lysis in a complement-
mediated hemolysis assay where as the control virus was able to inhibit hemolysis.  
This suggested C21 was needed to inhibit cell lysis.  The direct evidence that C21 had 
complement inhibitory activity was found when medium from RK-13 cells was 
chromatographed on a DEAE-Biogel column and the sample exhibiting the majority 




in which C21 was present.  Additionally, C21 was found to bind to the C4b 
complement protein [224].  Subsequent studies determined, via a complement-
enhanced neutralization assay, that the C21 protein was accountable for inhibition of 
the classical and alternative complement cascades in VACV infected cells possibly by 
interacting with both C4b and C3b.  Intradermal (ID) studies with rabbits also were 
able to show that the C21 null virus yielded smaller lesions than the VACV WR 
control demonstrating that C21 is involved in viral virulence [224-225]. 
1.6.4 Cytokines Reined In 
The B15R gene was predicted to encode a protein that had homology with the 
IL-1 receptor which suggested the protein may be involved in immune modulation of 
the host response to infection [226].  Subsequent studies demonstrated that B15 was 
expressed and secreted into the media of VACV infected cells and that it was able to 
specifically bind to IL-1β thus competitively inhibiting IL-1β from binding its natural 
receptor on T-cells.  To resolve if B15 was an important immune modulator for 
VACV mice were infected with a wild type VACV WR strain and a virus lacking the 
B15R ORF.  Mice that received the mutant virus lacking B15 had early onset of 
disease symptoms as compared with mice that received VACV WR suggesting B15 
contributes to the virulence of the virus [227]. 
Another secreted VACV protein that binds cytokines is encoded by the C12L 
gene.  When the discovery of human IL-18 binding protein (IL-18bp) was made it 
was noted that several poxviruses encoded a putative homologous protein [228].  IL-
18bp negatively regulates the pro-inflammatory cytokine IL-18 and therefore can 




found that the VACV C12L protein product is secreted from infected cells and 
inhibited IL-18 induced INF- γ production.  Furthermore, deletion of the C12L ORF 
attenuated the virus in Balb/C mice [229].   
The VACV Lister strain chemokine binding protein (vCKBP) was initially 
found while screening the medium of infected cells from many orthopoxviruses 
looking for a secreted viral chemokine binding protein [230].  The VACV WR A41L 
gene product has amino acid similarity to the Lister strain vCKBP and therefor  was 
analyzed in further studies to determine if it was involved in immune modulation and 
binding to CC chemokines.  Initial studies with the deletion of the ORF A41L 
demonstrated that A41 is dispensable for viral replication in cell culture but is 
required for full virus virulence in both an IN and ID model of infection.  An A41L 
deletion virus also exhibited an altered inflammatory response to infection [231].  
Additional studies made use of a purified A41 protein to screen for possible ligands.  
A41 was found to bind to CCL25, CCL26, CCL28, and CCL21.  Interestingly, when 
tested, A41 did not inhibit chemokine-induced chemotaxis as it was unable to 
competitively inhibit the binding of the chemokines with their cellular receptors.  A 
suggested alternative function for A43 is that it is used to block the interaction of 
chemokines with cell surface gags thereby changing the concentration gradient of the 
chemokines at the site of infection and leading to an altered immune response [232]. 
1.6.5 Meddling with IFN 
VACV B18R gene encodes a cell surface and secreted B18 protein which is a 
Type I IFN binding protein.  It has sequence homology with the α subunits of mouse, 




Deletion of B18R attenuates the virus in an IN mouse model of infection suggesting 
that when present it contributes to virus virulence [233-234]. 
The VACV gene B8R was discovered as an immune modulator due to its 
sequence similarity to the extracellular binding domain of the mouse and human IFN-
γ receptors.  It is expressed early and is secreted from VACV infected cells. B8 has 
been shown to bind and inhibit INF-γ from a wide range of species but despite the 
sequence similarity it has with the murine IFN-γ receptor, B8 does not have an 
affinity for mouse INF-γ.  However, the VACV protein B8 has been shown to 
function as a soluble IFN-γ decoy receptor and prevents antiviral effects typically 
seen by this cytokine [235-236].  Although there are conflicting reports on its 
virulence in mice, a B8 deletion virus is attenuated in rabbits [236-237]. 
1.6.6 Interference with IFN Induced Genes 
There are two genes expressed by VACV, E3L and K3L, that interfere with 
IFN induced double-stranded RNA-activated protein kinase (PKR) by different 
mechanisms; K3L is a decoy for eIF-2α phosphorylation by PKR while E3L 
competitively binds and sequesters dsRNA [238]. 
 At the outset of trying to determine proteins involved in VACV resistance to 
IFN, K3L was a candidate since it has 28% amino acid homology to eIF-2α.  The 
region of homology includes the site for serine phosphorylation by PKR.  Deletion of 
K3L from the VACV genome caused the virus to be sensitive to IFN [239].  
Transfection studies found that K3 inhibited eIF-2α phosphorylation and therefore 




inactive PKR and prevents PKR autophosphorylated activation which is the step 
preceding eIF-2α phosphorylation [241]. 
 The amino acid sequence of E3 was determined to have similarity to p25, a 
previously found VACV dsRNA binding protein implicated in inhibition of PKR 
[242-243].  E3 was demonstrated to inhibit the activity of PKR.  The C-terminal 
region of E3 also has similar homology to an RNA biding domain identified in the N-
terminal region of PKR [243-244].  Further studies were able to show that E3 
inhibited PKR by competitively binding to dsRNA [238]. Additionally, E3 has been 
shown to interfere with dsRNA and dsDNA induction of Type-1 IFN [245]. 
1.6.7 NF-κB Inhibition 
VACV strain MVA (modified vaccinia Ankara), unlike its parental Ankara 
virus, is missing many immune modulator genes and activates NF-κB upon infection.  
Infection/transfection studies with MVA and a 5.2-kb region of Ankara DNA restored 
the means for MVA to inhibit NF-κB.  This was determined by levels IκBα present as 
well as expression levels of NF- κB-transcriptionally regulated firefly luciferase.  The 
K1L ORF is one of the genes present in the 5.2-kb region of DNA from VACV 
Ankara that was used in the transfection study.  To test if this gene was responsible 
for preventing IκBα degradation it was inserted into the MVA genome and found that 
it did indeed prevent IκBα degradation and inhibition of NF-κB activation, although 
not to the same levels as a VACV WR control.   Thus, the KIL gene of VACV 
encodes a protein that hinders activation and subsequent translocation of NF-κB into 





 The observation was made that MVA can induce activation of NF-κB even 
when MVA infected cells are transfected with the K1L ORF.  Similarly, cells infected 
with a mutant VACV WR lacking the K1L gene exhibit a reduction in NF-κB 
activation suggesting additional protein involvement in NF-κB inhibition.  In 
addition, other pathways can be involved in activation of NF-κB in MVA infected 
cells; specifically MEK/ERK pathways.  The M2L ORF was another gene missing 
from MVA but present in the 5.2kb region from VACV Ankara strain mentioned 
above.  The M2L ORF was inserted into the MVA (MVA/M2) genome to test the 
ability of M2 to inhibit phosphorylation of ERK2.  Compared to control virus, ERK2 
phosphorylation was reduced in cells infected with MVA/M2 and subsequent 
mitigation of NF-κB activation [247]. 
 The VACV B14R ORF was initially studied since computational analyses 
indicated B14R was highly conserved in orthopoxviruses and it was located in a 
region of the genome rich in immunomodulators.  Deleting the gene from VACV 
allowed for the realization that B14 alters the inflammatory response and contributes 
to virus virulence in mice [248].  Subsequent studies show that B14 interacts with and 
inhibits the activity of the IKK subunit IKKβ and therefore prevents the downstream 
activation of NF-κB.  By preventing activation of NF-κB infected cells may not be 
able to induce an appropriate immune response which is consistent with what was 
exhibited when infecting mice with a B14 null virus in an ID mouse model.  Ensuing 
transfection studies demonstrated that B14 inhibits several inducers (e.g. TNFα and 




increase in phosphorylated IKKα  but not the IKKβ subunit suggesting B14 interacts 
with the IKKβ subunit of the IKK complex [249].  
Many signaling cascades involved in the activation of NF-κB converge on the 
protein IKK.  Over expression of N1 inhibited activation of NF-κB by binding IKK 
[250].  It is not surprising that IKK would be a target for viral immune modulators 
such as the N1 protein since many pathways involved in the immune response 
converge on the IKK complex.  There is, however, disagreement that N1 is involved 
in this aspect to immune modulation since it was unable to co-precipitate with the 
IKK complex and though it was able to inhibit IL-1 induced NF-κB activation in N1 
transfected cells the same was not true for infected cells [219, 249-251].  
1.6.8 Virulence Proteins with Unknown Functions 
 In addition to the above discussed VACV proteins involved in immune 
modulation and virulence there are many other proteins found to be important for full 
virus virulence as exhibited in animal models; however their exact mechanism of 
action is still unknown.  A summary of each of the proteins is found in Table 1-2 and 
includes the following proteins:  A14.5 [252], A39 [253], A40 [254], A55 [255], B7 





Table 1-2.  VACV virulence genes with unknown functions.  IN, ID (intradermal), 
and cell culture results are based on virus deletion of the specific gene.  No difference 
refers to the comparison of a delta virus with the wild type virus. 
 
   
Gene Time of 
Express
ion 
Localization IN Result ID Result Cell Culture Functional 
Motifs 
A14.5L Late Mature Virion Attenuated --- No Difference None 
A35R Early Viral Factories Attenuated --- No difference None 
A39R Late Secreted No Difference Quicker Lesion 
Resolution 
No Difference Semaphorin 
A40R Early Cell Surface No Difference Smaller Lesions No Difference None 




B7R Late Endoplasmic 
Reticulum 
No Difference Smaller Lesions No Difference None 








--- Similar Growth, Smaller 
Plaques 
None 
F3L Late --- No Difference Smaller Lesions No Difference BTB/Kelch 
Protein 
I5L Late Mature Virion Attenuated, 
Reduced Titers 
--- No Difference None 
A43R Late Golgi 
Complex/ 
Cell Surface 




Chapter 2: Vaccinia Virus Encodes a Small Hydrophobic Membrane 
Protein I5 that Enhances Replication and Virulence in Mice 
2.1 Introduction 
The Poxviridae, a family of complex DNA viruses that replicate solely in the 
cytoplasm of their host cells, are comprised of the Chordopoxvirinae and the 
Entomopoxvirinae subfamilies [1]. The orthopoxviruses, one of eight genera 
belonging to the chordopoxvirus subfamily, are the most intensively studied and best 
characterized poxviruses. VARV, a notorious member of this subfamily, has a host 
range that is restricted to humans and was the cause of smallpox until the disease was 
finally eradicated by immunization with VACV. The sequence similarity of many 
VACV and VARV genes is greater than 90%, accounting for the immunological 
cross-reactivity and vaccine efficacy. VACV has been propagated for more than 200 
years; it has become the laboratory prototype poxvirus and is widely employed as an 
expression vector [173]. The original host of VACV is unknown although it is 
currently endemic in parts of Brazil [260], and a closely related virus has been 
isolated from Mongolian horses [261].  
VACV has a linear double-stranded DNA genome with nearly 200 predicted 
open reading frames (ORFs). Only a few of the approximately 90 genes that are 
conserved in all chordopoxviruses [32] remain l rgely uncharacterized. One such 
protein, encoded by the I5L ORF, was identified as a component of the MV 
membrane by N-terminal sequencing of the fraction solubilized from purified MVs 




by the I5L ORF) with sucrose gradient-purified MVs was corroborated by mass 
spectroscopy [263-265]. Here, we show that I5 is expressed following viral DNA 
replication and is incorporated into the viral membrane at an early stage of 
morphogenesis. Despite its high conservation, I5 expression was not necessary or 
advantageous for virus replication a d spread in a variety of cultured cells. 
Nevertheless, I5 was important for virus replication and virulence in a mouse model, 
suggesting a role in host interactions.  
2.2 Materials and Methods 
2.2.1 Cells and Viruses 
 BS-C-1 cells were maintained in minimum essential medium with Earle's salts 
supplemented with 2% fetal bovine serum, 100 units/ml of penicillin, and 100 µg/ml 
of streptomycin. HeLa cells were maintained in Dulbecco's modified Eagle's medium 
supplemented with 2% fetal bovine serum and antibiotics as described above. The 
VACV Western Reserve (WR) strain and recombinant viruses were propagated as 
previously described [266]. 
2.2.2 Antibodies 
Rabbit antisera were raised against peptides derived from amino acids 38 to 
52(FTMQSLKFNRAVTIF) of the predicted I5 sequence and from amino acids 632 to 
643 (QYISARHITELF) of the A3 sequence plus a C-terminal cysteine required fo  




2.2.3 Plasmid and Recombinant VACV Construction 
To construct the recombinant vI5GFP, the flanking regions of the I5L ORF 
were amplified from VACV strain WR genomic DNA template using 
oligonucleotides ct66 (5'-CAT CAT CCA TTA GAA TTT TCA TT CCA CTA 
GCG TCA AAA AAT TTC CTA CT-3'), ct68 (5'-CAT AGA AAA AAA CAA AAT 
GAA ATT CTT ATA TCT AAA AAT TAG ATC AAA GAA  T3-'), ct69 (5'-ATG 
GAC GAG CTG TAC AAG TAA CGT CAA ATC CCT ATT AAT GAA AA-3'), 
and ct71 (5'-TCA TAC AAC TAT TTT GGT TTT AAA ACT TTG GAA AAA TCC 
TAC TTG TTG AAA-3'). The ORF for enhanced green fluorescent protein (GFP) 
under VACV promoter p11 was amplified from pA43GFF (unpublished data) using 
primers ct67 (5'-ATT CTT TGA TCT AAT TTT TAG ATA TAA GAA TTT CAT 
TTT GTT TTT TTC TAT G-3') and ct70 (5'-TTT TCA TTA ATA GGG ATT TGA 
CGT TAC TTG TAC AGC TCG TCC AT-3'). Primers ct67 and ct68 as well as ct69 
and ct70 were designed to complement each other. The above products were used in a 
second recombinant PCR to yield a GFP ORF flanked by regions up- and downstream 
of I5L. This construct preserved the last 28 nucleotides of the I5L ORF, which 
functions as a promoter for I4L. The resulting PCR product was gel purified and 
ligated into pCR-BluntII-Topo (Invitrogen, Carlsbad, CA), resulting in pI5GFP. The 
endogenous I5L ORF was replaced with the GFP marker gene by homologous 
recombination after transfection (Lipofectamine 2000; Invitrogen) of pI5GFP into 
VACV WR-infected cells. Recombinant viruses expressing GFP were detected with 
an inverted fluorescence microscope and isolated by three rounds of plaque 




Recombinant vI5HA-GFP (where I5HA is I5 carrying a hemagglutinin [HA] epitope 
tag) was made in a similar manner as vI5GFP. The primers ct81 (5'-CAT ACG ATG 
TTC CAG ACT ACG CTT AAG AAT TTC ATT TTG TTT TTT TCT A-3') and 
ct71 were used to amplify GFP under the p11 promoter from vI5GFP, and primers 
ct82 (5'-TTC TTA AGC GTA GTC TGG AAC ATC GTA TGG GTA ACT TTT 
CAT TAA TAG GGA-3') and ct66 were used to amplify I5L from VACV strain WR 
genomic DNA template. 
The I5 revertant virus (vI5Rev) and an I5 frameshift virus (vI5Stop) were 
derived from vI5GFP. Primers ct66 and ct71 were used to generate a PCR product 
containing the I5L gene including 500 bp of up- and downstream sequence. The 
resulting PCR product was gel purified and ligated into pCR-BluntII-Topo, resulting 
in pI5Rev. Homologous recombination was used to replace the GFP marker gene 
with the endogenous I5L ORF after transfection of pI5Rev into cells infected with 
vI5GFP. Non-GFP-expressing plaques were picked and isolated by three rounds of 
plaque purification. The correct site of recombination was verified by PCR and 
sequence analysis. A stop codon was generated in the I5L sequence of pI5Rev by 
using a QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) with 
PCR oligonucleotides containing the desired mutation. Primers ct91 (5'-GCA TAA 
CTG TAT TAA TGC TTT TGA TGT AAT TTC TGG TGC CGC CCT G-3') and 
ct92 (5'-CAG GGC GGC ACC AGA AAT TAC ATC AAA AGC ATT AAT ACA 
GTT ATG C-3') were used to delete nucleotide 61, resulting in an immediate stop 
codon. Homologous recombination was used to replace the GFP marker gene with the 




GFP-expressing plaques were picked and isolated by three rounds of plaque 
purification. The correct site of recombination was verified by PCR and sequence 
analysis. 
2.2.4 SDS-PAGE 
Cells were lysed in 0.2% NP-40 (10 mM Tris, pH 7.4, 10 mM CaCl2,
 10 mM 
NaCl) containing 8 µg/ml micrococcal nuclease (Worthington Bi chemical Corp., 
Lakewood, NJ) at 4°C for 20 min. After addition of lithium dodecyl sulfate sample 
buffer and reducing agent (Invitrogen, Carlsbad, CA), cell lysates were heated to 70°C 
for 10 min. Equal volumes of lysate were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% bis-Tris-MES [2-(N-
morpholino)ethanesulfonic acid]-SDS running buffer (Invitrogen). 
2.2.5 Western Blot Analysis 
Proteins separated by SDS-PAGE were electrophoretically transferred to 
polyvinylidene difluoride membrane (Invitrogen). Membranes w re blocked in Tris-
buffered saline with 5% nonfat dry milk and 0.05% Tween 20 and then incubated 
with antibodies for 1 h at room temperature or overnight at 4°C. Protein bands were 
visualized by chemiluminescence using West-Pico or Dura kits (Pierce Biotechnology 
Inc., Rockford, IL). 
2.2.6 Analysis of Virion Extracts 
VACV MVs, purified by two sucrose cushions and one sucrose gradient 
centrifugation from cells infected with vI5HA-GFP, were incubated t 37°C for 1 h in 




absence of 50 mM dithiothreitol (DTT). Soluble and insoluble fractions were 
separated by centrifugation at 30,000 x g for 30 min and resuspended to equal 
volumes in sample buffer containing lithium dodecyl sulfate. Equivalent amounts of 
each fraction were loaded on a 10% polyacrylamide gel and subjected to 
electrophoresis. The separated proteins were transferred to a polyvinylidene difluoride 
membrane and analyzed by Western blotting as described above. 
2.2.7 Confocal Microscopy 
HeLa cells were grown on glass coverslips in 12-well plates. C lls were 
infected at multiplicity of 0.5 PFU per cell. At 24 h post infection, cells were fixed 
with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 7 min at room 
temperature, washed three times with PBS, and then permeabilized for 10 min with 
0.1% Triton X-100 in PBS at room temperature. Cells were blocked for 1 h with 10% 
fetal bovine serum in PBS, followed by incubation with primary antibody at room 
temperature. Cells were washed three times in PBS, followed by incubation with 
Alexa Fluor 594-conjugated secondary antibody (Invitrogen) at room temperature. 
After cells were washed three times with PBS, DNA was stained with 4'-6'-
diamidino-2-phenylindole (DAPI), and coverslips were mounted on slides with 
Mowiol. Images were collected with a Leica TCS-NT/SP2 inverted confocal 
microscope system. 
2.2.8 Electron Microscopy 
BS-C-1 cells were grown in dishes of 60-mm diameter and infected wi h 5 




by fixing with 2% glutaraldehyde and embedding in EmBed-182 resin (Electron 
Microscopy Sciences, Hatfield, PA). Alternatively, cells were fix d with 4% 
paraformaldehyde-0.05% glutaraldehyde in 0.1 M phosphate buffer for 1 h at room 
temperature and incubated in 10% gelatin at 37°C. The cell pellet was collected by 
centrifugation, solidified on ice, cut at 4°C into small cubes infiltrated with 2.3 M 
sucrose in 0.1 M phosphate buffer, frozen on pins in liquid nitrogen, and cut into 70-
nm sections on a Leica Ultracut FCS microtome (Wetzlar, Germany). Cryosections 
were picked up on grids, thawed, washed free of sucrose, and stained with a 
monoclonal antibody to a HA epitope tag (Invitrogen) followed by rabbit anti-mouse 
immunoglobulin G (IgG) and protein A conjugated o 10-nm gold spheres. Specimens 
were viewed with an FEI-CM100 transmission electron microscope (Hillsboro, OR). 
2.2.9 Determination of Virulence in Mice 
Female BALB/c mice were purchased from Taconic (Germantown, NY) and 
maintained in a pathogen-free environment in sterile m croisolator cages. Groups (n = 
10) of 7-week-old mice were anesthetized by inhalation of isoflurane and inoculated 
via the IN route with a 20-µl suspension of purified VACV into one nostril. Mice 
were weighed daily for 2 weeks following challenge and were euthanized when they 
lost 30% of their initial body weight, according to a protocol approved by the National 
Institute of Allergy and Infectious Diseases Animal Care and Use Committee. 
Inoculum titers were determined in order to confirm the dose administered. 
2.2.10 Titration of Virus from Lung 




vI5Stop or vI5Rev; lungs were placed in 2 ml of PBS with 0.05% bovine serum 
albumin and kept at –80°C until use. Lungs were thawed and ground until a uniform 
homogenate was formed, frozen and thawed three times, and sonicated three times for 
30 s. Viral titers were determined by plaque assay on BS-C-1 cells.  
2.2.11 Histological Analysis 
A total of 17 mice were infected IN with 1 x 104 PFU of vI5Stop or vI5Rev 
and necropsied on days 3, 5, 7, and 10. Lungs were inflated with 10% neutral buffered 
formalin, and other tissues were also fixed in formalin and embedded in paraffin, and 
sections were stained with hematoxylin and eosin. Whole lung sections were prepared 
from each mouse. Histopathological changes in the nasal cavity were graded in a 
random, blinded fashion as to extent of tissue involvement and severity, with grades 
of 1 to 4 as indicated in the legend of Fig. 10.  For immunohistochemistry, a rabbit 
polyclonal antibody [267] was used at 1:2,000, followed by the Mach 4 horseradish 
peroxidase polymer (Biocare Medical, Concord, CA) and diaminobenzidine. 
2.3 Results 
2.3.1 Conservation of the I5L ORF in Chordopoxviruses 
The I5L ORF (VACV WR074) is predicted to encode a 79-amino-acid protein 
lacking cysteine, histidine, and tryptophan residues with a mass of approximately 8.7 
kDa. A hydrophilicity plot showed two putative transmembrane domains with very 
short N- and C-terminal sequences and only 18 amino acids between the two helices 
(Fig. 2-1A). The N-terminal sequence data of Takahashi and coworkers [262] 





Figure 2-1. Hydrophilicity of I5 and multiple sequence alignment of orthologs. 
(A) Hydrophilicity plot [268] of VACV I5. (B) A multiple sequence alignment was 
constructed using Jalview [269]. Sequences from eight orthopoxvirus species and one 
or more representatives of other chordopoxvirus genera were included in the 
alignment. Shading increases with the degree of amino acid conservation. The percent
identities between VACV WR074 and orthologs are listed on the right. 
Abbreviations: CPXV, cowpox virus; HSPV, horsepox virus; TATV, taterapox virus; 
CMLV, camelpox virus; ECTV, ectromelia virus; VARV, variola virus; MPXV 
monkeypox virus; TANV, tanapox virus; YMTV, yaba monkey tumor virus; ORFV, 
orf virus; LSCV, lumpyskin disease virus; MOCV, molluscum contagiosum virus; 




 found, nor were any functional sequence motifs predicted. However, all 
chordopoxvirus genomes sequenced to date contain an I5L ortholog 
(www.poxvirus.org). The amino acid sequence identities between I5 orthologs range 
from 94 to 100% among orthopoxviruses and 30 to 49% between members of 
different genera (Fig. 2-1B). 
2.3.2 The I5 Protein is Synthesized at Late Times During VACV Infection and 
Incorporated into Virions 
In order to specifically detect the I5 protein with antibody, we constructed a 
recombinant virus with an influenza virus HA epitope tag at the C terminus of I5 
without modifying the promoter, which contains a late consensus TAAATG motif 
[91]. To facilitate the isolation of the recombinant virus, we also inserted an ORF 
encoding GFP regulated by the VACV late p11 promoter between th  I5 and I4 
ORFs. The resulting virus, vI5HA-GFP, formed normal-size green plaques when 
viewed by fluorescence microscopy. At sequential times post-infection with vI5HA-
GFP, whole-cell extracts were analyzed by SDS-PAGE. The proteins were blotted to 
a membrane and probed with an antibody to the HA epitope tag. At 6 h after inf ction, 
a band that migrated with an estimated mass of approximately 9 kDa was detected. 
This band was increased in intensity from 8 to 24 h (Fig. 2-2A). A similar time course 
was found for the product of the A3L ORF (Fig.2-2A), a well-characterized late 
protein that appears as a doublet because of proteolytic processing [270]. Neither 
I5HA nor A3 was detected when cells were infected in the presence of cytosine 
arabinoside, indicating a requirement for viral DNA replication that was consistent 




Figure 2-2. Synthesis of I5 and MV membrane localization.  (A) I5 expression 
kinetics. BS-C-1 cells were infected with vI5HA-GFP at a multiplicity of 15 PFU per 
cell. At the indicated hours postinfection, cell extracts were prepared and analyzed by 
SDS-PAGE and Western blotting with antibody to the HA epitope tag. Masses (in 
kDa) of marker proteins are on the left. The blot was stripped and reprobed with 
antibody to the A3 protein, which appears as a doublet due to processing during virus 
maturation. M, mock infected. (B) Extraction of I5 from MVs. Sucrose gradient-
purified vI5HA-GFP MVs were treated with NP-40 or NP-40 and DTT or mock 
treated and separated into soluble (S) and pellet (P) fractions. Proteins in both 
fractions were resolved by SDS-PAGE, followed by Western blotting with antibody 




cells infected with vI5HA-GFP, and the presence of I5HA was demonstrated by 
Western blotting with antibody to the epitope tag. I5HA was mo tly extracted with  
1% NP-40 and completely solubilized when DTT was added, similar to the well-
characterized L1 MV membrane protein (Fig. 2-2B). This result supported previous 
data indicating that I5 is a component of the MV membrane. 
2.3.3 Localization of I5 to Viral Factories and Assembling Virions 
Confocal microscopy was performed to determine whether I5 associates with 
cellular membranes in addition to virions. Following infection with vI5HA-GFP, cells 
were fixed, permeabilized, and stained with antibody to the HA tag, followed by a 
fluorescently labeled secondary antibody. Cytoplasmic factories, the site of viral DNA 
replication and virion assembly, were visualized by staining with DAPI, which forms 
fluorescent complexes with double-stranded DNA. At late times after infection, 
factories may appear pleomorphic but are typically located adjacent to the nucleus, 
which also stains with DAPI. The I5 protein colocalized with viral factories (Fig. 3), 
consistent with incorporation into virus particles. A  a control, no specific antibody 
staining was found when cells were infected with an I5L deletion mutant (vI5GFP) to 
be described below (Fig. 2-3). Further experiments were carried out to determine the 
developmental stage at which I5 associates with viral membranes. Thawed 
cryosections of cells infected with vI5HA-GFP were stained with antibody to HA, 
followed successively by a secondary antibody and gold spheres conjugated to protein 
A. The grids were then examined by transmission EM. Gold grains were associated 
with IVs and MVs as well as later-stage wrapped forms and extracellular enveloped 






Figure 2-3. Localization of I5 in cytoplasmic viral factories.  HeLa cells were 
infected with vI5HA-GFP or vI5GFP at a multiplicity of 0.5 PFU per cell. After 24 
h, cells were fixed, permeabilized, and stained with anti-HA monoclonal antibody, 
followed by Alexa Fluor 594-conjugated anti-mouse antibody (red). DNA was 
stained with DAPI (blue). Images were viewed by confocal microscopy. Arrows 





Figure 2-4. Immunogold labeling of I5 associated with immature virions and 
MVs.  BS-C-1 cells were infected with vI5HA-GFP at a multiplicity of 5 PFU per 
cell. After 18 h, the cells were fixed and frozen. Thawed cryosections were incubated 
with mouse monoclonal antibody to HA, rabbit IgG to mouse IgG, and then with 10-
nm diameter gold particles conjugated to protein A. Electron microscopic images are 





 though some seemed to be more internal. An internal appearance can r sult from 
surface immunostaining of wedge-shaped sections [124]. 
2.3.4 I5 is Nonessential for Virus Replication in Cultured Cells 
In view of the conservation of I5, we suspected that the gene would be 
essential for virus replication. To confirm or refute this expectation, we transfected a 
plasmid containing the GFP ORF regulated by a late promoter between I5L flanking 
sequences into cells infected with VACV WR. An inability to isolate green 
fluorescent plaques would suggest that a deletion mutant was not viable. However, 
green plaques were readily isolated on BS-C-1 cells, and deletion of the I5L ORF was 
confirmed by PCR. Further characterization indicated no appreciable difference in 
plaques formed by vI5GFP and VACV WR on BSC1, BHK, CV-1, HeLa, HuTK–, 
and RK13 cells and on primary human epidermal keratinocytes, indicating normal 
virus replication and spread ( ata not shown). Moreover, the yields of vI5GFP and 
VACV WR in BS-C-1 cells were similar (data not shown). In addition, the 
morphologies of cells infected with the deletion mutant and wild-type virus were 
similar, without signs of nuclear fragmentation or cytoplasmic blebbing. 
Depending on the site of insertion, expression of GFP from a strong promoter 
can have subtle effects on virus replication, and this is particularly important if in vivo 
studies are planned. Therefore, we derived two additional viruses. Homologous 
recombination was used to replace the GFP ORF of vI5GFP with either the wild-type 
I5L ORF to generate the control vI5Rev or with the I5L ORF containing a deletion of 
nucleotide 61, resulting in an immediate stop c don, to generate vI5Stop. In both 




fluorescence and clonally purified. PCR and DNA sequencing confirmed the exp cted 
genome alterations. As expected, I5 could not be detected by Western blotting of 
lysates of cells infected with either vI5GFP or vI5Stop, indicating premature 
translational termination i  the latter case (Fig. 2-5C). The plaque sizes and virus 
yields of vI5Stop and vI5Rev were indistinguishable (Fig. 2-5A & 2-5B). 
Furthermore, all stages of morphogenesis appeared normal as determined by 
transmission EM (Fig.2-6). 
2.3.5 I5 Contributes to Virulence in Mice 
The conservation of I5 suggested an important function despite the ability of 
vI5GFP and vI5Stop to replicate in cultured cells. We therefore considered the 
possibility that I5 has a role in host interactions that might be discerned only in vivo. 
An IN mouse model of infection [271] was used to determine if expression of I5 is 
important for virulence. Groups of 10 mice received 104, 105, or 106 PFU of vI5Rev 
or vI5Stop IN under anesthesia. Weight change and survival were recorded daily and 
compared to an uninfected control group. All mice that received 1 x 104 PFU of 
vI5Stop survived and exhibited less severe weight loss (P = 0.0003, day 7; Mann 
Whitney test) than mice that received the same amount of vI5Rev (Fig.2-7). More 
decisively, mice that received 1 x 105 PFU of vI5Stop had a 90% survival rate while 
mice that received 1 x 105 PFU of vI5Rev had a 0% survival rate (Fig. 2-7A). 
However, with a challenge dose of 1 x 106 PFU, there were no survivors in any of the 
groups (data not shown). Thus, I5 is important for virulence although vI5Stop was 




Figure 2-5. Comparison of vI5Stop and vI5Rev replication.  (A) Plaque 
phenotypes of vI5Rev and vI5Stop. Monolayers of BS-C-1 cells were infected with 
vI5Rev or vI5Stop. After 48 h, cells were fixed and stained with crystal violet. (B) 
One-step growth curves of vI5Rev and vI5Stop. BS-C-1 cells were infected with 
vI5Rev or vI5Stop at a multiplicity of 10 PFU per cell. Virus yields were determined 
from 2 to 24 h postinfection by plaque assay. (C) Western blots. Proteins in lysatesof 
cells that were infected with vI5GFP (lane 1), vI5HA-GFP (lane 2), vI5Stop (lane 
3), or vI5Rev (lane 4) were resolved by SDS-PAGE and analyzed by Western blotting 





Figure 2-6. Transmission electron microscopy of cells infected with vI5Stop and 
vI5Rev.  BS-C-1 cells were infected with vI5Stop or vI5Rev at a multiplicity of 5 
PFU per cell. At 20 h after infection, the cells were fixed and prepared for EM. 
Electron microscopic images are shown with a 200-nm scale bar. IV, immature 




Figure 2-7. Virulence of vI5Stop and vI5Rev in mouse IN infection model.  
Groups of 10 BALB/c mice were inoculated intranasally with 104or 105PFU of 
purified vI5Stop or vI5Rev. (A) Percent survival of mice. (B) Percentage of original 
weight of mice. WC, untreated and uninfected weight control. Symbols in panels A 




2.3.6 I5 Enhances VACV Replication in the Lung 
Previous studies have shown that high titers of VACV WR occur in the lungs  
following IN inoculation and that this correlates with morbidity and death [272-275]. 
In order to compare the spread of vI5Stop and vI5Rev in the lower respiratory tract, 
we inoculated a sublethal dose of 1 x 104 PFU of vI5Stop and vI5Rev IN and 
quantified viral titers in the lungs on days 3, 5, and 7. The titers of vI5Rev and 
vI5Stop on day 3 were similar, suggesting that I5 was not required to establish an 
initial infection (Fig.2-8A). However, on day 5 the amount of vI5Stop began to 
decline, whereas the amount of vI5Rev increased (Fig. 2-8A). This trend continued on 
day 7, indicating that the vI5Stop virus was cleared rapidly. To confirm these results, 
the experiment was repeated with a large number of mice (n = 10) in each group, and 
the day 7 lung titers were determined. Although the weights of the lungs from the 
mice infected with vI5Stop were slightly higher than those of vI5Rev, the virus lung 
titers were significantly lower (P = 0.0002) (Fig. 2-8B). These results confirmed the 
lower progression and more rapid clearance of vI5Stop from the host. 
2.3.7 Pathology Induced by vI5Stop and vI5Rev 
Mice were infected IN with 1 x 104 PFU of vI5Stop or vI5Rev as described in 
the preceding section. Upper and lower respiratory tract tissue sections were 
examined by staining with hematoxylin a d eosin and antibodies to VACV in order to 
discern differences in virulence. Both viruses infected the nasal epithelium and 
underlying glandular tissues. Destruction of the nasal epithelium occurred without 






Figure 2-8. Virus titers in the lungs of infected mice.  BALB/c mice were 
inoculated IN with 1 x 104 PFU of purified vI5Stop or vI5Rev. Lungs were excised, 
weighed, and then titers were determined by plaque assay to determine virus load. (A) 
Viral titers per gram of lung tissue obtained on days 3, 5, and 7. Titers were 
determined on lungs from three mice infected with each virus, and standard errors of 
the mean are indicated. (B) Lung weights and viral titers on day 7. Lung weights, 
viral titer/lung, and viral titer/gram of lung are plotted. Titers were detrmined on 
lungs from 10 mice infected with each virus, and standard errors of the mean are 
shown. A Mann Whitney t test yielded a P value of 0.005 in a comparison of the lung 
weights from mice infected with the two viruses and a P value of 0.0002 in a 






Figure 2-9. Immunostained sections of nasal epithelium and lung from infected 
mice.  Mice were infected IN with 1 x 104 PFU of vI5Stop or vI5Rev. Nasal sections 
and lung tissue were fixed in formalin and paraffin embedded. Histochemistry was 
performed with an antibody to VACV proteins. Images are at a magnification of 
x100. (A) Nasal epithelium infected with vI5Stop at day 7. Note the focus of infection 
stained brown. (B) Nasal epithelium infected with vI5Rev at day 7. Note the extent of 
the lesions and abundant antigen. (C) Lung infected with vI5Stop at day 5 showing 
one bronchiole infected with associated necrosis and inflammation. (D) Lung infected 




Figure 2-10. Graded lesions of nasal epithelium on indicated days after infection 
with vI5Stop and vI5Rev.  Two to three sections of the nasal cavity (including the 
squamous, respiratory, and olfactory regions of the epithelium) from each of the 17 
mice in this study were stained with antibody to VACV. The entire slide was scanned 
to make a virtual computerized slide and a section representing average antigen
expression for each mouse was selected. After an initial examination, grading was 
done in a random blinded fashion as follows: 0, no stained foci seen; 1, few positive 
focal areas; 2 several positive foci or large positive areas; 3, many positive foc  or 




vI5Stop were less severe and more focal than those caused by vI5Rev (Fig. 2-9A and 
2-9B). Furthermore, the severity and extent of the lesions produced by vI5Stop 
decreased after day 7 whereas those produced by vI5Rev continued to increase (Fig. 
2-10). With both viruses, infection of the lungs occurred focally in the bronchiolar 
epithelial cells and around bronchioles. The lesions and viral infection appeared less 
severe in the mice receiving vI5Stop than in vI5Rev-infected mice, and in both cases 
the pathology was less extensive than in the nasal c vities (Fig. 2-9C and 2-9D). 
2.4 Discussion 
 We have provided the first detailed characterization of the product of the I5L 
gene of VACV. Although previous studies had suggested that I5 is a component of 
the MV membrane [276], its function was not predicted because of the absence of any 
recognizable functional motif or nonpoxvirus homolog. We confirmed the association 
of I5 with the MV membrane by biochemical and electron microscopic methods. 
Expression of I5 was dependent on viral DNA replication, and the protein was 
associated with the membranes of both immature and MVs in viral factories. I5 was 
not detected in association with cell membranes, at first suggesting that it func ioned 
in some aspect of the virus life cycle such as virion assembly or spread. Nevertheless, 
the I5L gene was readily deleted, and the mutant virus replicated and spread normally 
in a variety of host cells. This result was surprising because I5L is conserved in all 
chordopoxviruses, implying an important function. Thus, it was interesting to find 
that the deletion and frameshift mutants that did not express I5 were attenuated in a 
murine IN infection model. Thus, with an inoculum of 1 x 105 PFU (approximately 




challenge dose 10 times higher, there were no survivors. 
In anesthetized mice, the IN route results in primary infections in the upper 
and lower respiratory tracts, and the latter has been associated with morbidity and 
death [272-275, 277]. With a nonlethal dose of 104 PFU, on day 3 the lung titers of the 
I5L frameshift mutant and control VACV were similar, suggesting that the mutant 
virus was able to initially infect and replicate th re. However, by day 7 the titer in 
mouse lungs of the mutant was approximately 3 logs lower than the control, 
indicating less progression or more rapid clearance of the mutant. Examination of 
histological sections also indicated necrosis of the epithelium and underlying 
glandular tissue in the nasal passages of both the I5L mutant and the control virus at 
early times. However, there was less progression of the infection with the mutant 
virus than with the control virus and considerable recovery b tween days 7 and 10 
relative to the control virus. 
Our data suggest that I5 is involved in repelling the host antiviral defense 
though we cannot rule out some differences in cell tropism in vivo. Indeed, the latter 
would make sense in view of the location of I5 in the MV membrane. Further studies 
with a variety of primary mouse cells may help to evaluate this possibility. There have 
been a number of reports indicating that VACV triggers signaling pathways during 
the attachment or entry stage of infection [45, 278-279], which could be mediated or 
partially suppressed by an MV membrane protein. Some information regarding these 
possibilities might be obtained in follow-up studies by analysis of inflammatory cells 
and cytokines in mouse lung washes as well as in in vitro studies. The I5 protein is 




transmembrane segments. There is a highly conserved 18-amino-acid sequence 
located between the two helices that could be an interaction domain for some cellular 
protein, and efforts to test this hypothesis are planned. A14.5, an even smaller 
conserved MV membrane protein of only 53 amino acids with a similar predicted 
topology, is also nonessential in cell culture but is required for virulence [280]. It will 




Chapter 3:  Vaccinia Virus A43R Gene Encodes an Orthopoxvirus-
Specific Late Non-Virion Type-1 Membrane Protein that is 
Dispensable for Replication but Enhances Intradermal Lesion 
Formation 
3.1 Introduction 
The poxviruses are a group of large and complex DNA viruses that replicate 
exclusively in the cytoplasm of their host cells.  The Poxviridae are divided into two 
subfamilies, the chordopoxviruses, which infect vertebrates, and the 
entomopoxviruses, which infect invertebrates [1].  The orthopoxviruses are one of the 
eight genera belonging to the Chordopoxviruses.  The two most well known 
poxviruses belonging to the orthopoxvirus genus are: VARV, the causative agent of 
smallpox and VACV the vaccinating agent used to eradicate smallpox.  VACV is the 
prototype poxvirus.  It has a linear double stranded DNA genome that is 
approximately 190kbs with covalently closed hairpin termini.  VACV encodes ~ 200 
genes of which almost half are completely conserved within the chordopoxvirus 
subfamily [32]. The evolutionarily conserved genes tend to be centrally located 
within the genome and are mostly involved in essential replication functions, while 
the genus- and species-specific genes are nearer the ends of the genome and typically 
involved in host interactions. 
Many of the genes found within the variable region of the genome encode for 
proteins involved in virus virulence.  Virulence proteins can be implicated in various 




host immune modulation.  Viral immune modulators are a diverse group of proteins 
that function in many of ways to fight and/or modulate the host immune system.  
There are viral regulators of apoptosis [281] and inflammation [246], proteins to 
interfere with the complement cascade [224], as well as ones that inhibit IFN induced 
genes [240] .  VACV encodes for many immune modulators such as the VACV B15R 
gene product, a secreted IL-1beta binding protein [227], the B18 gene product, a Type 
I IFN binding protein [234], and the E3L gene product which blocks PKR activation 
by binding dsRNA  [243, 282]. Since not all VACV genes have been characterized, it 
seems likely that additional proteins involved in host interactions will be discovered.  
The A43R open reading frame (ORF) is a candidate as it is embedded within 
the variable region of the genome. For example, the A41L ORF encodes a chemokine 
binding protein [283] and the protein encoded by A46R inhibits TLR signaling [221].  
This study provides the initial characterization of A43, the product of the A43R ORF, 
which was expressed after viral DNA replication as a glycosylated protein that 
associated with Golgi and plasma membranes but was not appreciably incorporated 
into virus particles. The gene was found to be dispensable for VACV replication in 
cell culture but caused smaller than normal intradermal lesions in mice. 
3.2 Materials and Methods 
3.2.1 Cells and Viruses 
BS-C-1 cells were maintained in minimum essential medium with Earle's salts 
supplemented with 2% fetal bovine serum, 100 units/ml of penicillin, and 100 µg/ml 




supplemented with 2% fetal bovine serum and antibiotics as described above. The 
VACV Western Reserve (WR) strain and recombinant viruses were propagated as 
previously described [266]. 
3.2.2 Plasmid and Recombinant VACV Construction 
To construct the recombinant v∆A43GFP, the flanking regions of the A43R 
ORF were amplified from VACV strain WR genomic DNA template using 
oligonucleotides ct49 (5'- ATG CTA ATG TCA AGT TTA TTC CAA TAG ATG 
TCT TAT TAA AAA ACA TAT AT-3'), ct51 (5'-CAT AGA AAA AAA CAA AAT  
GAA ATT CTT AAA ATT GAC ACT ACA TAT GAA TAT-3'), ct52 (5'- GCA 
TGG ACG AGC TGT ACA AGT AAT TAT GCT ATG CTA TTA GAA ATG -3'), 
and ct54 (5'- CTA TTT AGA AAA CCA TCA CTA CTC AAC AAC TAT ACG 
TTG AAG ATA TCC AAC -3'). The ORF for enhanced green fluorescent protein 
(GFP) under VACV promoter p11 was mplified using primers ct50 (5'- ATA TTC 
ATA TGT AGT GTC AAT TTT AAG AAT TTC ATT TTG TTT TTT TCT ATG 3') 
and ct53 (5'- CAT TTC TAA TAG CAT AGC ATA ATT ACT TGT ACA GCT CGT 
CCA TGC -3'). Primers ct50 and ct51 as well as ct52 and ct53 were designed to 
complement each other. The above products were used in a second recombinant PCR 
to yield a GFP ORF flanked by regions up- and downstream of A43R.  The resulting 
PCR product was gel purified and ligated into pCR-BluntII-Topo (Invitrogen, 
Carlsbad, CA), resulting in p∆A43GFP. The endogenous A43R ORF was replaced 
with the GFP marker gene by homologous recombination fter transfection 
(Lipofectamine 2000; Invitrogen) of p∆A43GFP into VACV WR-infected cells. 




microscope and isolated by three rounds of plaque purification. The correct site of 
recombination was verified by PCR analysis.  A similar procedure was used to delete 
the A43R ORF from the IHD-J strain of VACV to form IHD∆A43GFP. 
Recombinant vA43V5 was derived from v∆A43GFP. The primers ct61 (5'- 
AAT GCT AAT GTC AAG TTT ATT CCA ATA GAT GTC TTA TTA AAA ACA 
TAT AT -3'), ct62 (5'- ACC GAG GAG AGG GTT AGG GAT AGG CTT ACC 
AGA GTT CAT TTT TAT TTT TTT -3'), ct63 (5'- TAT CCC TAA CCC TCT CCT 
CGG TCT CGA TTC TAC GTA ATT ATG CTA TGC TAT TA -3'), and ct54 were 
used to amplify A43R from genomic DNA and incorporate a C-terminal V5 tag. Non-
fluorescent plaques were picked and clonally purified by repeated isolations.   
The A43 revertant virus (vA43Rev) was derived from v∆A43GFP.  Primers 
ct61 and ct54 were used to generate a PCR product containing the A43R gene 
including 500 bp up- and downstream sequence. The PCR product was gel purified 
and ligated into pCR-BluntII-Topo (pA43Rev). Homologous recombination was used 
to replace the GFP marker gene with the endogenous A43R ORF after transfection of 
pA43Rev into cells infected with v∆A43GFP. Non-GFP-expressing plaques were 
picked and isolated by three rounds of plaque purification. The correct site of 
recombination was verified by PCR and sequence a alysis. An A43V5- virus 
(vA43V5Stop) was also derived from v∆A43GFP. A stop codon was generated in the 
A43R sequence of pA43V5 by using a QuickChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA) with PCR oligonucleotides containing the desired 
mutation. Primers ct79 (5'- CCG GTA TTG GCA TAC AGC TAA TCG ATT TTT 




CGA TTA GCT GTA TGC CAA TAC CGG -3') were used to change nucleotide 68, 
resulting in an immediate stop codon. Homologous recombination was used to replace 
the GFP marker gene with the A43V5Stop sequence after transfection of 
pA43V5Stop into v∆A43GFP-infected cells. Again, non-GFP-expressing plaques 
were picked and isolated by three rounds of plaque purification. The correct site of 
recombination was verified by PCR and sequence a alysis. 
Primers ct61 (5'- AAT GCT AAT GTC AAG TTT ATT CCA ATA GAT 
GTC TTA TTA AAA ACA TAT AT -3'), ct88 (5'- TAC CCA TAC GAT GTT CCA 
GAC TAC GCT TAA TTA TGC TAT GCT ATT AGA AAT -3'), ct89 (5'- TAA 
TTA AGC GTA GTC TGG AAC ATC GTA TGG GTA AGA GTT CAT TTT TAT 
TTT TTT -3'), and ct54 were used to amplify A43R from genomic DNA and 
incorporate a C-terminal HA tag.   The PCR product was gel purified and ligated into 
pCR-BluntII-Topo (pA43HA).  pN65Q, pN93Q, and N114Q were generated in the 
A43R sequence of pA43HA by using a QuickChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA) with PCR oligonucleotides containing the desired 
mutation. Primers ct101 (5'- CCA TAT AGA TAT AAT TTT ATT CAG CGC ACG 
TTA ACC GTA GAT GAA C -3') and ct102 (5'- GTT CAT CTA CGG TTA ACG 
TGC GCT GAA TAA AAT TAT ATC TAT ATG G -3') were used for pN65Q. 
Primers ct103 (5'- CAC AAA TAT GGT TCA CTT CAG CCT AGT TTG ATT GTC 
TCA TTA TC -3') and ct104 (5'- GAT AAT GAG ACA ATC AAA CTA GGC TGA 
AGT GAA CCA TAT TTG TG -3') were used for pN93Q. Primers ct105 (5'- CAA 
TGC TCA GTA CAG GTA TCG TGT CTC ATT AAA AAT TTG GC -3') and ct106 




were used for pN114Q.  pA43HA∆TM was constructed from WR genomic DNA 
using primers ct64 (5'-TAA TTA AAA TAA AAA GTA ATA TTC ATA TGT AGT 
GTC AAT TTT AAA TGA TGA -3') and ct90 (5'- TTA AGC GTA GTC TGG AAC 
ATC GTA TGG GTA ATT ATA CTT GTC ATT TAT ATC TTT AT -3') in a PCR 
reaction to amplify the A43 coding region under the natural promoter, delete the 
transmembrane domain and maintain the HA tag sequence.  The PCR product was gel 
purified and ligated into pCR-BluntII-Topo (pA43HA∆TM).  All constructed plasmid 
sequences and mutations were verified by sequence analysis. 
The plasmid pcDNAA43V5 was constructed by amplifying A43V5 from 
pA43V5 using primers ct85 (5'- CAC CAT GAT GAT GAT GAA ATG GAT AAT 
ATC CAT ATT-3') and ct86 (5'- TTA CGT AGA ATC GAG ACC GAG GAG AGG 
-3').   The PCR product was then gel purified and ligated into vector pcDNA3.1 
(Invitrogen) forming pcDNAA43V5. 
3.2.3 Endo H and PNGase Treatment of Cell Lysate 
BSC-1 cells were infected with vA43V5 and harvested 24hours post infection.  
Cell lysates were treated with either Peptide: N-Glycosidase F (New England 
BioLabs) or Endoglycosidase H (New England BioLabs) for 2-24 hours.  Samples 
were analyzed by SDS-Page and Western blotting. 
3.2.4 EV Purification 
RK-13 cells were infected with either WR or vA43V5.  48 h post-infection, 
the media supernatant was harvested and clarified by low-speed centrifugation for 20 




were gently resuspended and further purified by layering over a preformed CsCl 
gradient as described previously [165] and centrifuged using a SW-41 rotor at 32,000 
rpm for 4 h at 20°C.  Fractions collected starting from the top of the tube were loaded 
on a 10% polyacrylamide gel and subjected to electrophoresis. The separated proteins 
were transferred to a polyvinylidene difluoride membrane and analyzed by Western 
blotting. 
3.2.5 MV Purification 
WR or vA43V5 infected RK-13 cells were scraped and collected by low-speed 
centrifugation.  Cells were then resuspended and disrupted by Dounce 
homogenization.  Cell suspensions were clarified by low-speed centrifugation and 
MV purified by centrifugation through two 36% sucrose cushions and one 25-40% 
sucrose gradient.   
3.2.6 SDS-PAGE 
 Cells were lysed in 0.2% NP-40 (10 mM Tris, pH 7.4, 10 mM CaCl2,
 10 mM 
NaCl) containing 8 µg/ml micrococcal nuclease (Worthington Bi chemical Corp., 
Lakewood, NJ) at 4°C for 20 min. After addition of lithium dodecyl sulfate sample 
buffer and reducing agent (Invitrogen, Carlsbad, CA), cell lysates were heated to 70°C 
for 10 min. Equal volumes of lysate were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% bis-Tris-MES [2-(N-




3.2.7 Western Blot Analysis 
Proteins separated by SDS-PAGE were electrophoretically transferred to 
polyvinylidene difluoride membrane (Invitrogen). Membranes w re blocked in Tris-
buffered saline with 5% nonfat dry milk and 0.05% Tween 20 and then incubated 
with antibodies for 1 h at room temperature or overnight at 4°C. Protein bands were 
visualized by chemiluminescence using West-Pico or Dura kits (Pierce Biotechnology 
Inc., Rockford, IL). 
3.2.8 Confocal Microscopy 
HeLa cells were grown on glass cover slips in 12-well plates. C lls were 
infected at multiplicity of 0.5 PFU per cell. At 24 h post infection, cells were fixed 
with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 7 min at room 
temperature, washed three times with PBS, and then permeabilized for 10 min with 
0.1% Triton X-100 in PBS at room temperature. Cells were blocked for 1 h with 10% 
fetal bovine serum in PBS, followed by incubation with primary antibody at room 
temperature. Cells were washed three times in PBS, followed by incubation with 
Alexa Fluor-conjugated secondary antibody (Invitrogen) at room temperature. After 
cells were washed three times with PBS, DNA was stained with 4'-6'-diamidino-2-
phenylindole (DAPI), and coverslips were mounted on slides with Mowiol. Images 
were collected with a Leica TCS-NT/SP2 inverted confocal microscope system. 
3.2.9 Cell Surface Biotinylation 
HeLa cells were infected with vA43V5. At 18 h post infection, cells were 




of the membrane-impermeable EZ-Link Sulfo-NHS-LC-Biotin (sulfosuccinimidyl-6-
[biotinamido] hexanoate) (Pierce) dissolved in PBS on ice for 20 min. Cells were 
washed with PBS and quenched with 10% fetal bovine serum for 20 min on ice and 
then washed twice again. Cells were then lysed and the biotinylated proteins were 
affinity purified on a NeutrAvidin gel (Pierce). 
3.2.10 IN Infection Model 
Female BALB/c mice were purchased from Taconic (Germantown, NY) and 
maintained in a pathogen-free environment in sterile m croisolator cages. Groups of 
7-week-old mice were anesthetized by inhalation of isoflurane and inoculated via the 
IN route with a 20-µl suspension of purified VACV into one nostril. Mice were 
weighed daily for 2 weeks following challenge and were euthanized when they lost 
30% of their initial body weight, according to a protocol approved by the National 
Institute of Allergy and Infectious Diseases Animal Care and Use Committee. The 
inocula were titered in order to confirm the dose administered.  
3.2.11 Ear Pinna Infection Model 
Female BALB/c mice were anaesthetized with avertin and inoculated 
intradermally with 10 PFU of VACV in a 10-µl suspension. Lesions were measured 
daily with a micrometer. Ears were removed and placed in 2 ml of PBS with 0.05% 
bovine serum albumin and kept at –80°C until use. Ears were thawed, cut into 1 mm 
pieces and treated with collagenase for 3-4 h at 37°C, frozen and thawed three times, 
and sonicated three times for 30 s. Viral titers were determined by plaque assay on 





3.3.1 A43R is Conserved Among Orthopoxviruses 
The A43R ORF (VACV WR168) is predicted to encode a 194-amino-acid 
protein with an N-terminal hydrophobic domain, two N-linked glycosylation sites, 
and a C-terminal transmembrane domain.  The SignalP program [284] predicted that 
the N-terminal hydrophobic region is a cleaved signal sequence with the cleavage 
occurring between S22 and S23.  A43R is highly conserved within all 
orthopoxviruses; the sequence identity is >94% except for ectromelia virus which has 
a 78% identity (Fig. 3-1). However, there are no recognized homologs in any other 
poxvirus genus, nor are there non-poxvirus homologs or functional motifs to help 
predict the function of A43.  
3.3.2 A43 is a Glycosylated Protein Expressed at the Late Stage of VACV 
Replication 
A recombinant virus, in which a V5 epitope tag was added to the C-terminus 
of A43, was constructed to assist in protein characterization. The region upstream 
containing the promoter sequence was unaltered so as not to perturb expression. The 
growth kinetics and plaque phenotype of vA43V5 were similar to that of the parental 





Figure 3-1.  Multiple sequence alignment of A43 orthologs.  Jalview [269] was 
used to construct a multiple sequence alignment of A43 from eight orthopoxvirus 
species.  Abbreviations:  VACV-WR, VACV strain WR, CMLV-M96, camelpox 
virus strain M96; CPXV-BR, cowpox virus strain Brighton; ECTV-Mos, ectromelia 
virus strain Moscow; MPXV-WR267, monkeypox virus strain Walter Reed 267; 
RPXV, rabbitpox virus strain Utrecht; VACV-MVA, VACV strain Modified VACV 








The A43R promoter contains the late consensus sequence TAAATG.  To 
examine the expression kinetics of A43V5 BSC-1 cells were infected with vA43V5 
either in the presence or absence of the DNA replication inhibitor, cytosine  
arabinoside (Ara C).  At different times post infection, whole cell lysates were
analyzed by SDS-PAGE and Western blotting.  A band corresponding to the size of 
A43V5 was detected at 6 hours post infection and continued to accumulate up 
through 24 hours post infection (Fig. 3-2A).  These results were compared with the 
well characterized, late expressed, A3 protein and found similar expression kinetics 
(Fig. 3-2A).  Additionally, A43 went undetected in cells infected in the presence of 
Ara C (data not shown), which is indicative of VACV proteins expressed at the late 
stage of infection. 
Inspection of the predicted amino acid sequence of A43 revealed three 
potential N-glycosylation sites that could account for the relatively slow 
electrophoretic migration of A43. To determine the state of glycosylation of A43, a 
whole cell lysate from vA43V5 infected cells was divided into portions that were 
untreated or treated with Peptide: N-Glycosidase F (PNGase F) or Endoglycosidase H 
(Endo H). PNGase F is capable of removing all types of N-linked oligosaccharides, 
whereas Endo H removes only high mannose and some hybrid types of 
oligosaccharides. Both glycosidases caused an increase in the mobility of A43V5 as 
determined by SDS-PAGE and Western blotting (Fig. 3-2B), consistent with N-






Figure 3-2.  A43 synthesis and glycosylation.  (A) Western blot analysis of A43 
expression kinetics.  BS-C-1 cells were infected at a multiplicity of 10 PFU per cell 
with vA43V5.  At 0, 2, 4, 8 12 and 24 hours post infection whole cell lysates were 
analyzed by SDS-PAGE and Western blotting with an antibody to the V5 epitope tag.  
The blot was stripped and reprobed with an antibody to the VACV late protein A3. 
Position and mass in kDa of marker proteins are shown on the left.  (B) vA43V5 
infected cell lysates were treated with (+) or without (-) Endo H or PNGase F nd 






3.3.3 A43 has Two N-linked Glycosylation Sites 
To determine the number and the specific sites of glycosylation, three 
plasmids (pA43HAN65Q, pA43HAN93Q, pA43HAN114Q) were constructed to 
express the A43R gene under its natural promoter each with a C-terminal HA epitope 
tag and each carrying a mutation in one of the three predicted N-linked glycosylation 
sites.  A fourth plasmid was also constructed to express A43R also under its natural 
promoter with an HA epitope tag but without any mutation present (pA43HA).  An 
A43 deletion virus, v∆A43GFP (see methods) was also constructed for use in the 
subsequent infection/transfection experiments with the plasmids.   
To confirm the expression of A43 with the mutations in each of the three N-
X-S/T consensus sequences, BSC-1 cells were infected with v∆A43GFP and then 
transfected with pN65Q, pN93Q, pN114Q, or pA43HA.  Cells were lysed and 
extracts were analyzed by Western blotting using an antibody to the HA epitope tag 
(Fig. 3-3A).  If each of the N-X-S/T consensus sequences were actual sites for 
glycosylation then one would expect to see an increase in the mobility for each sit  
that was disrupted by mutation as compared to the A43HA.  Two of the three 
mutants, A43HAN65Q and A43HAN93Q, migrated faster than the intact A43HA.  
These data suggest A43 has two N-linked glycosylation sites.  To confirm this 
finding, infected/transfected cell lysate was briefly treated with PNGase F and the 
protein migration patterns were analyzed (Fig. 3-3B).  As anticipated, cl avage of 1-2 
glycosylations was observed in each sample.  Both A43HA and A43HAN93Q had 
similar patterns since neither had their glycosylation sites altered and both 






Figure 3-3.  A43 has two N-linked oligosaccharides.  (A) Expression of pA43HA, 
pN65Q, pN93Q, pN114Q.  BS-C-1 cells were infected with v∆A43GFP and 
transfected with either one of four plasmids:  pA43HA, pN65Q, pN93Q, pN114Q.   
Cell extracts were analyzed by SDS-PAGE and Western blotting with ant-HA 
antibody.  (B)  Partial (+) or mock (-) PNGase digestion of cell extracts 24 hours after 
infection with v∆A43GFP and transfection with pA43HA, pN65Q, pN93Q, or 








each had one site for glycosylation still intact.  These results provide another piec  of 
evidence to support the finding that A43 has two N-linked glycosylations. 
3.3.4 A43 is Not Incorporated into the Virion 
 The recombinant virus, vA43V5 was utilized to determine whether A43 is a 
component of the MV or EV membrane.  After RK-13 cells were infected with 
vA43V5, EVs were purified from the media supernatant on a CsCl density gradient 
and the MVs were purified by two sucrose cushions followed by a sucrose density 
gradient.  Purified virions as well as whole cell extracts were analyzed by SDS-PAGE 
and immunoblotting.  A43 was readily detected in whole cell lysate but not at all 
detected in EV extracts and just barely detectable in MV extracts (Fig. 3-4).  Both 
membranes were stripped and re-probed with either the EV protein B5 or the MV 
core protein A3.  B5 and A3 were detected in similar amounts in the EV extract and 
MV extract, respectively, as well as the whole cell lysate.  The slight detection of A43 
in MVs can be attributed to the small amount of cellular membranes acquired during 
virion morphogenesis or to contamination from cell debris during the purification 
process.  Since there is a much higher detection of A43 in whole cell lysate it is 
presumed A43 is associated with cell membranes and not associated with the viral 
membranes.   
3.3.5 The A43 is a Type-1 Transmembrane Protein Localizing to the Golgi 
Complex as well as to the Plasma Membrane 
A43 was primarily detected in whole cell extract so the next step would be to 









Figure 3-4.  Distribution of A43 in EV and MV and whole cell extract.  RK-13 
cells were infected with vA43V5.  EV and MV were purified from media or cell 
lysates, respectively (methods).    Antibody to the EV protein B5 was used to 
compare the presence of the protein in EV with total cell extracts.  Antibody to the
MV core protein A3 was used to compare the presence of the MV protein with total 
cell extract.  Antibody to V5 epitope tag on A43 was used to analyze the presence of 






cells infected with vA43V5.  After infection, cells were fixed, permeabilized, and 
stained with an anti-V5 antibody followed by a fluorescently labeled secondary  
antibody.  Infected cells were also stained with either DAPI or HOECHTS; both are 
known to form fluorescent complexes with DNA.  This allowed for the visualization 
of cytoplasmic viral factories, the site of viral DNA replication and virion assembly, 
as well as for visualization of the cell nucleus.  The A43V5 protein colocalized with 
β-cop, a specific Golgi complex protein, suggesting A43 localizes to the Golgi 
complex (Fig. 3-5). 
Additionally, a plasmid expressing A43V5 under the cytomegalovirus 
promoter was transfected into uninfected cells and co-localization of A43 with a 
Golgi membrane marker was again visualized by confocal microscopy.  These data 
indicate A43 has the ability to enter the secretory pathway independent of a viral 
infection (Fig. 3-6). 
Confocal microscopy was also used to determine the topology of A43.  
vA43V5 infected cells were either left unpermeabilized or treated with digiton n o 
selectively permeabilize the plasma membrane.  The V5 epitope tag on A43 was only 
detected in digitonin-permeabilized cells and not in unpermeabilized cells suggestin  
the V5 tag is cytoplasmic.  The V5 tag was added to the C-terminus of the A43V5 
protein therefore detection of A43 in cells permeabilized with digitonin provides 
evidence that A43 is a type-1 transmembrane protein.  These data are consistent with 
the previous finding that A43 is glycosylated, as the N-X-S/T consensus sequence 
would have to be luminal for glycosylation modification to occur.  As a control, cells 





Figure 3-5.  Intracellular localization of A43.  HeLa cells were infected with 
VACV-WR or vA43V5 at a multiplicity of .05.  24 hours after infection, cells were 
fixed, permeabilized and stained with an anti-V5 antibody as well as an anti-Beta-
Cop antibody followed by fluorescently labeled secondary antibodies (red and gree 
respectively).  DNA was stained with DAPI (blue).  Confocal microscopy was used to 









Figure 3-6.  Intracellular localization of A43 in uninfected cells.  BS-C-1 cells 
were either non-transfected or transfected with pcDNA.A43V5.  24 hours after 
transfection, cells were fixed, permeabilized and stained with an anti-V5 antibody as 
well as an anti-Beta-Cop antibody followed by fluorescently labeled secondary 
antibodies (red and green respectively).  DNA was stained with DAPI (blue).  








type-1 transmembrane EV protein that can also be found at the cell surface as well as 
in the Golgi complex. The antibody to B5 recognizes an epitope in the luminal, N- 
terminal domain of the protein [158] and is able to recognize B5 at the plasma 
membrane when cells are either unpermeabilized or digitonin-permeabilized (Fg. 3-
7). 
In addition to detecting A43V5 in the Golgi apparatus, A43V5 was also 
unexpectedly detected at the plasma membrane (Fig. 3-7).  To confirm that A43 
traffics through the secretory pathway the plasmid pA43HA∆TM was constructed in 
which the putative transmembrane domain of A43 was removed.  BSC-1 cells were 
then infected with v∆A43GFP and transfected with the plasmid pA43HA∆TM.  24 
hours post infection media supernatant was harvested and TCA precipitated at the 
same time as the infected cells were harvested and lysed.  Samples were analyz d by 
SDS-PAGE and Western blotting.  A43HA was only detected in the lysate while 
A43HA∆TM was detected in both the lysate and as a secreted protein in the medium 
(Fig. 3-8A). 
In order to verify that A43 traffics to the plasma membrane during a VACV 
infection vA43V5 infected cells were surface labeled with biotin in the presenc or 
absence of Brefeldin A.  Brefeldin A inhibits the transport of proteins from the ER to 
the Golgi complex but does not interfere with production of MVs in a VACV 
infection [285].  An affinity pull down was then performed from the labeled cells and 
we found that A43V5 was indeed affinity purified from the cells that were not treated 
with Brefeldin A (Fig. 3-8B) suggesting A43V5 transits to the plasma membrane 






Figure 3-7.  Topology of A43.  vA43V5 infected HeLa cells were fixed and left 
unpermeabilized (top panels) or permeabilized with digitonin (bottom panels).  Cells 
were then stained with an antibody to the EV protein B5 (green) as well as with an 
antibody to the V5 epitope tag (red) followed by fluorescently labeled secondary 
antibodies.  DAPI or Hochest were used to stain DNA (blue).  Confocal microscopy 







Figure 3-8.  Intracellular trafficking of A43.  (A) BS-C-1 cells were infected with 
v∆A43GFP followed by transfection with plasmids expressing full length HA-tagged 
A43 (pA43HA) or a truncated version missing the transmembrane domain 
(pA43HA∆TM).  After 24 hours, cells lysates (L) and TCA precipitated media 
supernatant (M) were analyzed by Western blotting with an antibody to the HA tag. 
(B) HeLa cells were infected with vA43V5.  18 hours post infection, cells surfaces 
were labeled with a membrane-impermeable biotin reagent.  Biotinylated proteins 
were affinity purified on NeutrAvidin beads and input (I), unbound (U), and bound 





3.3.6 A43 is a Non-Essential Protein, Dispensable for VACV Replication, 
Growth, and Cell-to-Cell Spread in Cultured Cells 
To investigate the function of A43 in the virus life cycle an A43 deletion 
mutant was made from the VACV WR strain.  A plasmid carrying a GFP ORF under 
the VACV P11 late promoter and between A43R flanking sequences was transfected 
into cells infected with VACV WR.  GFP expressing plaques were readily detected, 
isolated, and purified suggesting A43 was deleted by homologous recombination and 
hence non-essential for viral replication.  The deletion of A43R was confirmed by 
PCR and sequence analysis.  BS-C-1 cells were infected with the parental VACV or 
the recombinant v∆A43GFP viruses and at different times after infection viral yields 
were determined and were not significantly different (Fig. 3-9A).  Additionally, BS-
C-1 cells were infected with the parental VACV or the recombinant v∆A43GFP 
viruses and 48 hours post infection cells were fixed and stained with crystal violet to 
view plaque formation, which appears similar between the two viruses (Fig. 3-9B) 
The deletion virus also had normal replication and spread in BHK, CV-1, HeLa, 
RK13 (Fig. 3-10), A549 cells (not shown) and primary human epidermal 
keratinocytes (not shown).  Furthermore, all stages of morphogenesis appeared 
normal in v∆A43GFP infected cells as determined by transmission EM (Fig. 3-11). 
An A43 deletion was also constructed in the IHD-J strain of VACV.  This was 
done to determine if A43 has any involvement in the release of the virus from 
infected cells.  The IHD-J strain is known for forming comet-shaped plaques due to a 





Figure 3-9. Replication of an A43R deletion mutant in tissue culture cells. (A) 
One-step growth curve. BS-C-1 cells were infected at a multiplicity of 10 PFU/cell 
with v∆A43GFP and VACV WR. Virus yields were determined at the indicated times 
post infection by plaque assay. (B) Formation of v∆A43GFP and VACV WR plaques. 
BS-C-1 cells were infected with v∆A43GFP and VACV WR. Cells were fixed and 
stained with crystal violet at 48 h after infection. (C) Formation of IHD∆A43GFP and 
VACV IHD-J plaques. BS-C-1 cells were infected with IHD∆A43GFP and VACV 








Figure 3-10.  Plaque phenotype of WR-GFP and v∆A43GFP in different cell 
lines.  Phase contrast images of individual plaques from either WR-GFP or 












Figure 3-11. Transmission electron microscopy of cells infected with vA43Stop.  
BS-C-1 cells were infected with vA43Stop at a multiplicity of 5 PFU per cell. At 20 h 
after infection, the cells were fixed and prepared for EM. Electron microscopic 
images are shown with a 250-nm scale bar. C, crescents; NU, nucleoid; IV, immature 







released is due to a point mutation in the A34R gene [287].  However, deletion of 
A43 from VACV IHD-J strain had no effect on comet formation (Fig. 3-9C). 
3.3.7 A43 is Required for Full Virus Virulence in a Murine Intradermal Model 
In cell culture, v∆A43GFP did not exhibit a difference in virus yields as 
compared with WR.  With this in mind and considering the placement of A43R in the 
viral genome, it was hypothesized that A43 is involved in virus virulence. Further 
characterization of v∆A43 in animals would require the construction of two 
additional viruses.  A revertant virus was constructed replacing GFP ORF with the 
wild type A43R ORF (vA43Rev).  This was necessary to verify that any effect se n 
with the deletion virus was caused by the desired gene deletion and not by some 
additional random mutation.  The second virus needed was a non GFP-expressing 
A43 deletion virus where the GFP ORF was replaced by the A43V5 ORF which 
contained a point mutation at nucleotide 68, resulting in an immediate stop codon 
(vA43V5stop). 
Two mouse models were used to determine the virulence of v∆A43V5 as 
compared to vA43Rev.  Initially, the virulence in an IN respiratory model was 
evaluated [271].  At a dose of 104 PFU, weight loss between the two groups was 
similar (Fig. 3-12A) and all but one vA43Rev infected mouse survived (Fig. 3-12B).  
At a dose of 105 PFU, of the mice that received vA43Stop none survived and of the 
mice receiving vA43Rev, three of ten survived (Fig. 3-12B).  None of the mice 
survived in either group with a dose of 106 PFU (data not shown).  The second model 
used was an ID model that has been described previously [288-289].  This is an 




infection remains localized to the ear pinna.  Groups 5 BALB/c mice were 
anesthetized and challenged intradermally with 104 PFU of purified vA43V5stop or 
vA43Rev.  Once lesions appeared, they were measured daily using digital calipers.  
Mice that received vA43stop had significantly smaller lesions over the entirecou se 
of the infection (p=.001; Mann Whitney test) than the mice that received vA43Rev 
(Fig. 3-13A).  In C57BL/6 mice lesions produced by vA43V5stop were also smaller 
than lesions in the mice that received vA43Rev (p=.005) (Fig. 3-14).  Balb/C mice 
had a larger difference in lesions size between the two viruses than seen with the 
C57BL/6 mice.  Viral yields were quantified from Balb/C mice that had been 
intradermally infected with vA43V5 or vA43Rev.  Despite the smaller lesions found 
in mice ID infected with vA43V5stop, there was no difference in viral yields (Fig 3-
13B). 
3.4 Discussion 
This report is the first initial characterization of the VACV virus gene A43R.  
Although A43R is highly conserved amongst orthopoxvirus there are no non-poxvirus 
homologs or recognizable functional motifs to elucidate its function.  It was found 
that A43 is a type-1 transmembrane protein that is expressed late in a VACV 
infection and is modified by the addition of two high-mannose or hybrid types of 
glycosylations.  A43 did not associate with the virion but the protein localizes to both 
the Golgi complex as well as to the plasma membrane suggesting A43 may play  
role in host interactions.  Although A43 was not required for replication and growth 









Figure 3-12.  Virulence of A43R null mutant after respiratory infection. Groups 
(n = 10) of 7-week-old mice were inoculated via the IN route with 104 or 105 PFU of 
VACV.  Mice were weighed daily for 2 weeks following challenge and were 
euthanized when they lost 30% of their initial body weight.  (A) Percentage of 
original weight of mice. WC, untreated and uninfected weight control. Symbols in 





Figure 3-13. Intradermal replication and lesion formation by A43R null mutant 
in Balb/C mice. (A) Groups of Balb/C mice were infected intradermally in the ear 
pinnae with 104 PFU of vA43Rev or vA43V5Stop. Lesion sizes were determined 
daily with digital calipers to the nearest 0.5 mm. Standard errors of the mean are 
shown. (B) Mice were sacrificed and virus titers were determined from three 





Figure 3-14.  Intradermal lesion formation by A43R null mutant in C57BL/6 
mice.  (A) Groups of C57BL/6 mice were infected intradermally in the ear pinnae 
with 104 PFU of vA43Rev or vA43V5Stop.  Lesion sizes were determined daily with 




smaller lesions in a murine ID infection model suggesting A43 is required for full 
virus virulence.  A43 is not the first VACV protein that, when deleted, reduces virus 
virulence but not viral replication.  Similar to A43 is the B7R gene which when 
deleted also produced smaller lesions in the ID mouse model and also had no 
difference in viral titer [256].  A40, also found at the plasma membrane but not in EV 
[254], was also reported to produce smaller lesions [290] but there are no reports 
indicating a reduction in viral replication.   
The bulk of the A43 protein is found within the lumen of the Golgi complex 
as well as in the extracellular environment of the cell.  It is possible that A43 is 
sequestering a host defense molecule within the Golgi complex preventing its 
secretion and/or at the same time interacting with that or another host defense protein 
at the cell surface and thus preventing it from inducing a signaling cascade.  Although 
able to see a small effect on virulence after infection of mice with the vA43V5stop 
virus, it is possible that A43 might be more host specific.  The full effects of the 
deletion are difficult to see since the animal model used is not the natural host for 
VACV.  It might be interesting to try deleting A43 from the ectromelia virus and then 




Chapter 4:  Conclusions  
4.1 Conclusion 
 There are two main objectives for elucidating the strategies used by viruses to 
inhibit and to manipulate the host responses to infection.  First, the knowledge will 
enhance our understanding of viral pathogenesis. Second, insight into how viruses 
manipulate and inhibit certain host responses can lead to further comprehension of 
those particular host pathways.  There is, however, no precise systematic method for 
identifying virulence genes.  The multifaceted actions of the immune response t  a 
viral infection cannot be reproduced in tissue culture and although inspection of the 
viral genome may lead to suspicious candidates there are often virulence genes with 
no identifying markers. 
Historically, attenuated viruses obtained experimentally were often found to 
harbor multiple mutations.  It was often difficult to find the contributory factor to an 
attenuated phenotype considering all essential viral genes are also virulence genes 
and one would have to ascertain the genes specifically involved in host immune 
modulation and not just viral replication. Methods used now for predicting immune 
modulators are easier, however, once an immune modulating gene is determined, 
further studies must be done to in order to define its mechanism of action. This only 
adds to the complexity of studying such genes.  Different methods have been utiliz d 
for identifying immunomodulators in the poxviruses such as, computational 
comparisons, which reveal sequence homology between VACV proteins and host 




activity of proteins secreted from infected cells; and a reverse genetics approach 
which allows for phenotypic analysis following the deletion of a gene from the viral 
genome. 
The work presented in this dissertation includes the first account of two 
VACV genes that had not previously been described:  I5L and A43R.  Through this 
initial characterization, both I5 and A43 were found to be important for the virulence 
of VACV.  My project focused on discovering the characteristics of I5 and A43 that 
could aid in the eventual elucidation of these proteins functions. 
The major conclusions regarding I5 are that the protein (i) is conserved in all 
chordopoxviruses but not in non-poxviruses; (ii) contains no obvious functional 
motifs; (iii) is a late protein expressed after viral DNA replication; (iii) is specifically 
associated with the MV membrane but not with EV nor cell membranes; (iv) is 
dispensable for replication in tissue culture cells; (vii) null mutant are attenuated in 
mice by IN route.   
Considering its high conservation in all chordopoxviruses and association 
with immature and MVs it was expected that I5 would contribute to the VACV life 
cycle, however, it was not essential for replication in cell culture and even more 
surprising it was necessary for full virus virulence in mice.  Lung titer data from IN 
inoculation with the I5L frameshift mutant revealed that the virus was able to initially 
infect and replicate in the lung but progression was limited and the virus was cleared 
more rapidly than the control revertant virus.  Given that I5 is on the surface of the 
MV, it is entirely possible that I5 may be involved in cell tropism since only a limited 




sequence located between the two transmembrane domains may be important for 
interaction with a cellular protein and initial studies to test cellular binding of I5 have 
been favorable. 
The major conclusions regarding A43 are that the protein (i) is conserved in 
all orthopoxviruses but not other poxvirus genera or non-poxviruses; (ii) contains no 
obvious functional motifs; (iii) is a late protein expressed after viral DNA replication; 
(iii) is not specifically associated with MVs or EVs; (iv) contains N-linked 
oligosaccharides at two sites; (iv) concentrates in Golgi membranes and traffics to 
plasma membrane; (v) exhibits a type 1 membrane topology; (vi) is dispensable for 
replication in tissue culture cells; (vii) null mutant retains virulence in mice by IN 
route; and (viii) null mutant produces smaller ID lesions in mice. 
Because of the predicted late promoter and transmembrane domain, it was 
anticipated that A43 would be an EV membrane protein and have a role in virus 
egress. Nevertheless, this was not the case as A43 was not associated with the EV and 
neither plaque size nor comet formation was altered. Indeed, with regard to tissue 
culture studies A43R null mutants were indistinguishable in every respect from the 
parental WR or IHD-J strain of VACV. In view of these results, it was suspected that 
A43 is likely to be involved in host interactions and that the null mutant would be 
attenuated in animal models. It was surprising therefore to find that the A43 null 
mutant was as virulent as the revertant in the mouse IN model. However, the null 
mutant made smaller lesions than the revertant in mouse ear pinnae when injected 
intradermally. The increased thickness of the lesion is due to proliferation of 




that replication of VACV in the ear pinna reaches a peak on day 4-5 and the titer is 
declining before the lesion reaches a maximal size several days later [291]. Despite 
the difference in lesion size, the titers of mutant and revertant viruses were similar to 
each other at all time points. The similar titers may be related to the observation that 
the same amounts of virus are produced when the inocula vary over a 100-fold range 
[291]. Unreduced titers and smaller lesions were also found with the B7R deletion 
mutant [256].  
Taken together the above characteristics differentiate A43R from other 
replication dispensable genes. The majority of such genes have early rather th n late 
promoters, which would seem to be generally advantageous if the product interacts 
with the host. The five previously characterized replication dispensable late genes 
consist of A14.5L [292], A39R [293-294], A55R [295], B7R [256], I5L [296] and 
F3L [297]. Except for A55R, absence of the gene resulted in attenuation in either the 
IN (A14.5, I5L) or ID (A39, B7R, F3L) mouse model. Loss of A55 actually increased 
skin lesion size. As pointed out above, the B7R and A43R null mutants exhibited 
decreased skin lesion size. The retention of virulence in the IN mode by the B7R null 
mutant was also similar to that of the A43R mutant [256]. There are, however, 
substantial differences between B7 and A43; B7 localizes in the lumen of the ER 
whereas A43 is a type 1 membrane protein in Golgi and plasma membranes. It had 
been suggested that B7 might sequester a cell protein in the ER, though that has not 
yet been demonstrated. Although A43 might also act by sequestering a cell protein in 
the Golgi apparatus, its presence on the plasma membrane suggests that it intercts 




The coexistence of virus and host has imposed selective pressure on 
both the virus defenses and the host offense.  15% of VACV expressed proteins 
are directly involved immune modulation and therefore add to virus virulence and 
pathogenesis.  Some of these proteins are structurally similar and functionally similar 
to host proteins, some are structurally similar but function in an unexpected capacity, 
and some have completely novel structure and function.  At the same time, the host 
has developed an astonishing system able to attack viruses and virally 
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